Cool the Inflamed Brain: A Novel Anti-inflammatory Strategy for the Treatment of Major Depressive Disorder

World Health Organization. Factsheets: Depression., Available from: www.who.int/news-room/fact-sheets/detail/depression (Accessed on: Aug 31 2022).

James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; Abdollahpour, I.; Abdulkader, R.S.; Abebe, Z.; Abera, S.F.; Abil, O.Z.; Abraha, H.N.; Abu-Raddad, L.J.; Abu-Rmeileh, N.M.E.; Accrombessi, M.M.K.; Acharya, D.; Acharya, P.; Ackerman, I.N.; Adamu, A.A.; Adebayo, O.M.; Adekanmbi, V.; Adetokunboh, O.O.; Adib, M.G.; Adsuar, J.C.; Afanvi, K.A.; Afarideh, M.; Afshin, A.; Agarwal, G.; Agesa, K.M.; Aggarwal, R.; Aghayan, S.A.; Agrawal, S.; Ahmadi, A.; Ahmadi, M.; Ahmadieh, H.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akinyemiju, T.; Akseer, N.; Al-Aly, Z.; Al-Eyadhy, A.; Al-Mekhlafi, H.M.; Al-Raddadi, R.M.; Alahdab, F.; Alam, K.; Alam, T.; Alashi, A.; Alavian, S.M.; Alene, K.A.; Alijanzadeh, M.; Alizadeh-Navaei, R.; Aljunid, S.M.; Alkerwi, A.; Alla, F.; Allebeck, P.; Alouani, M.M.L.; Altirkawi, K.; Alvis-Guzman, N.; Amare, A.T.; Aminde, L.N.; Ammar, W.; Amoako, Y.A.; Anber, N.H.; Andrei, C.L.; Androudi, S.; Animut, M.D.; Anjomshoa, M.; Ansha, M.G.; Antonio, C.A.T.; Anwari, P.; Arabloo, J.; Arauz, A.; Aremu, O.; Ariani, F.; Armoon, B.; Ärnlöv, J.; Arora, A.; Artaman, A.; Aryal, K.K.; Asayesh, H.; Asghar, R.J.; Ataro, Z.; Atre, S.R.; Ausloos, M.; Avila-Burgos, L.; Avokpaho, E.F.G.A.; Awasthi, A.; Ayala Quintanilla, B.P.; Ayer, R.; Azzopardi, P.S.; Babazadeh, A.; Badali, H.; Badawi, A.; Bali, A.G.; Ballesteros, K.E.; Ballew, S.H.; Banach, M.; Banoub, J.A.M.; Banstola, A.; Barac, A.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Barrero, L.H.; Baune, B.T.; Bazargan-Hejazi, S.; Bedi, N.; Beghi, E.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Belachew, A.B.; Belay, Y.A.; Bell, M.L.; Bello, A.K.; Bensenor, I.M.; Bernabe, E.; Bernstein, R.S.; Beuran, M.; Beyranvand, T.; Bhala, N.; Bhattarai, S.; Bhaumik, S.; Bhutta, Z.A.; Biadgo, B.; Bijani, A.; Bikbov, B.; Bilano, V.; Bililign, N.; Bin Sayeed, M.S.; Bisanzio, D.; Blacker, B.F.; Blyth, F.M.; Bou-Orm, I.R.; Boufous, S.; Bourne, R.; Brady, O.J.; Brainin, M.; Brant, L.C.; Brazinova, A.; Breitborde, N.J.K.; Brenner, H.; Briant, P.S.; Briggs, A.M.; Briko, A.N.; Britton, G.; Brugha, T.; Buchbinder, R.; Busse, R.; Butt, Z.A.; Cahuana-Hurtado, L.; Cano, J.; Cárdenas, R.; Carrero, J.J.; Carter, A.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castillo Rivas, J.; Castro, F.; Catalá-López, F.; Cercy, K.M.; Cerin, E.; Chaiah, Y.; Chang, A.R.; Chang, H-Y.; Chang, J-C.; Charlson, F.J.; Chattopadhyay, A.; Chattu, V.K.; Chaturvedi, P.; Chiang, P.P-C.; Chin, K.L.; Chitheer, A.; Choi, J-Y.J.; Chowdhury, R.; Christensen, H.; Christopher, D.J.; Cicuttini, F.M.; Ciobanu, L.G.; Cirillo, M.; Claro, R.M.; Collado-Mateo, D.; Cooper, C.; Coresh, J.; Cortesi, P.A.; Cortinovis, M.; Costa, M.; Cousin, E.; Criqui, M.H.; Cromwell, E.A.; Cross, M.; Crump, J.A.; Dadi, A.F.; Dandona, L.; Dandona, R.; Dargan, P.I.; Daryani, A.; Das Gupta, R.; Das Neves, J.; Dasa, T.T.; Davey, G.; Davis, A.C.; Davitoiu, D.V.; De Courten, B.; De La Hoz, F.P.; De Leo, D.; De Neve, J-W.; Degefa, M.G.; Degenhardt, L.; Deiparine, S.; Dellavalle, R.P.; Demoz, G.T.; Deribe, K.; Dervenis, N.; Des Jarlais, D.C.; Dessie, G.A.; Dey, S.; Dharmaratne, S.D.; Dinberu, M.T.; Dirac, M.A.; Djalalinia, S.; Doan, L.; Dokova, K.; Doku, D.T.; Dorsey, E.R.; Doyle, K.E.; Driscoll, T.R.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Duncan, B.B.; Duraes, A.R.; Ebrahimi, H.; Ebrahimpour, S.; Echko, M.M.; Edvardsson, D.; Effiong, A.; Ehrlich, J.R.; El Bcheraoui, C.; El Sayed Zaki, M.; El-Khatib, Z.; Elkout, H.; Elyazar, I.R.F.; Enayati, A.; Endries, A.Y.; Er, B.; Erskine, H.E.; Eshrati, B.; Eskandarieh, S.; Esteghamati, A.; Esteghamati, S.; Fakhim, H.; Fallah Omrani, V.; Faramarzi, M.; Fareed, M.; Farhadi, F.; Farid, T.A.; Farinha, C.S.E.; Farioli, A.; Faro, A.; Farvid, M.S.; Farzadfar, F.; Feigin, V.L.; Fentahun, N.; Fereshtehnejad, S-M.; Fernandes, E.; Fernandes, J.C.; Ferrari, A.J.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fitzmaurice, C.; Foigt, N.A.; Foreman, K.J.; Fox, J.; Frank, T.D.; Fukumoto, T.; Fullman, N.; Fürst, T.; Furtado, J.M.; Futran, N.D.; Gall, S.; Ganji, M.; Gankpe, F.G.; Garcia-Basteiro, A.L.; Gardner, W.M.; Gebre, A.K.; Gebremedhin, A.T.; Gebremichael, T.G.; Gelano, T.F.; Geleijnse, J.M.; Genova-Maleras, R.; Geramo, Y.C.D.; Gething, P.W.; Gezae, K.E.; Ghadiri, K.; Ghasemi Falavarjani, K.; Ghasemi-Kasman, M.; Ghimire, M.; Ghosh, R.; Ghoshal, A.G.; Giampaoli, S.; Gill, P.S.; Gill, T.K.; Ginawi, I.A.; Giussani, G.; Gnedovskaya, E.V.; Goldberg, E.M.; Goli, S.; Gómez-Dantés, H.; Gona, P.N.; Gopalani, S.V.; Gorman, T.M.; Goulart, A.C.; Goulart, B.N.G.; Grada, A.; Grams, M.E.; Grosso, G.; Gugnani, H.C.; Guo, Y.; Gupta, P.C.; Gupta, R.; Gupta, R.; Gupta, T.; Gyawali, B.; Haagsma, J.A.; Hachinski, V.; Hafezi-Nejad, N.; Haghparast Bidgoli, H.; Hagos, T.B.; Hailu, G.B.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Handal, A.J.; Hankey, G.J.; Hao, Y.; Harb, H.L.; Harikrishnan, S.; Haro, J.M.; Hasan, M.; Hassankhani, H.; Hassen, H.Y.; Havmoeller, R.; Hawley, C.N.; Hay, R.J.; Hay, S.I.; Hedayatizadeh-Omran, A.; Heibati, B.; Hendrie, D.; Henok, A.; Herteliu, C.; Heydarpour, S.; Hibstu, D.T.; Hoang, H.T.; Hoek, H.W.; Hoffman, H.J.; Hole, M.K.; Homaie Rad, E.; Hoogar, P.; Hosgood, H.D.; Hosseini, S.M.; Hosseinzadeh, M.; Hostiuc, M.; Hostiuc, S.; Hotez, P.J.; Hoy, D.G.; Hsairi, M.; Htet, A.S.; Hu, G.; Huang, J.J.; Huynh, C.K.; Iburg, K.M.; Ikeda, C.T.; Ileanu, B.; Ilesanmi, O.S.; Iqbal, U.; Irvani, S.S.N.; Irvine, C.M.S.; Islam, S.M.S.; Islami, F.; Jacobsen, K.H.; Jahangiry, L.; Jahanmehr, N.; Jain, S.K.; Jakovljevic, M.; Javanbakht, M.; Jayatilleke, A.U.; Jeemon, P.; Jha, R.P.; Jha, V.; Ji, J.S.; Johnson, C.O.; Jonas, J.B.; Jozwiak, J.J.; Jungari, S.B.; Jürisson, M.; Kabir, Z.; Kadel, R.; Kahsay, A.; Kalani, R.; Kanchan, T.; Karami, M.; Karami Matin, B.; Karch, A.; Karema, C.; Karimi, N.; Karimi, S.M.; Kasaeian, A.; Kassa, D.H.; Kassa, G.M.; Kassa, T.D.; Kassebaum, N.J.; Katikireddi, S.V.; Kawakami, N.; Karyani, A.K.; Keighobadi, M.M.; Keiyoro, P.N.; Kemmer, L.; Kemp, G.R.; Kengne, A.P.; Keren, A.; Khader, Y.S.; Khafaei, B.; Khafaie, M.A.; Khajavi, A.; Khalil, I.A.; Khan, E.A.; Khan, M.S.; Khan, M.A.; Khang, Y-H.; Khazaei, M.; Khoja, A.T.; Khosravi, A.; Khosravi, M.H.; Kiadaliri, A.A.; Kiirithio, D.N.; Kim, C-I.; Kim, D.; Kim, P.; Kim, Y-E.; Kim, Y.J.; Kimokoti, R.W.; Kinfu, Y.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Knudsen, A.K.S.; Kocarnik, J.M.; Kochhar, S.; Kokubo, Y.; Kolola, T.; Kopec, J.A.; Kosen, S.; Kotsakis, G.A.; Koul, P.A.; Koyanagi, A.; Kravchenko, M.A.; Krishan, K.; Krohn, K.J.; Kuate, Defo B.; Kucuk Bicer, B.; Kumar, G.A.; Kumar, M.; Kyu, H.H.; Lad, D.P.; Lad, S.D.; Lafranconi, A.; Lalloo, R.; Lallukka, T.; Lami, F.H.; Lansingh, V.C.; Latifi, A.; Lau, K.M-M.; Lazarus, J.V.; Leasher, J.L.; Ledesma, J.R.; Lee, P.H.; Leigh, J.; Leung, J.; Levi, M.; Lewycka, S.; Li, S.; Li, Y.; Liao, Y.; Liben, M.L.; Lim, L-L.; Lim, S.S.; Liu, S.; Lodha, R.; Looker, K.J.; Lopez, A.D.; Lorkowski, S.; Lotufo, P.A.; Low, N.; Lozano, R.; Lucas, T.C.D.; Lucchesi, L.R.; Lunevicius, R.; Lyons, R.A.; Ma, S.; Macarayan, E.R.K.; Mackay, M.T.; Madotto, F.; Magdy Abd El Razek, H.; Magdy Abd El Razek, M.; Maghavani, D.P.; Mahotra, N.B.; Mai, H.T.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Mamun, A.A.; Manda, A-L.; Manguerra, H.; Manhertz, T.; Mansournia, M.A.; Mantovani, L.G.; Mapoma, C.C.; Maravilla, J.C.; Marcenes, W.; Marks, A.; Martins-Melo, F.R.; Martopullo, I.; März, W.; Marzan, M.B.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Mathur, M.R.; Matsushita, K.; Maulik, P.K.; Mazidi, M.; McAlinden, C.; McGrath, J.J.; McKee, M.; Mehndiratta, M.M.; Mehrotra, R.; Mehta, K.M.; Mehta, V.; Mejia-Rodriguez, F.; Mekonen, T.; Melese, A.; Melku, M.; Meltzer, M.; Memiah, P.T.N.; Memish, Z.A.; Mendoza, W.; Mengistu, D.T.; Mengistu, G.; Mensah, G.A.; Mereta, S.T.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Mezerji, N.M.G.; Miazgowski, B.; Miazgowski, T.; Millear, A.I.; Miller, T.R.; Miltz, B.; Mini, G.K.; Mirarefin, M.; Mirrakhimov, E.M.; Misganaw, A.T.; Mitchell, P.B.; Mitiku, H.; Moazen, B.; Mohajer, B.; Mohammad, K.A.; Mohammadifard, N.; Mohammadnia-Afrouzi, M.; Mohammed, M.A.; Mohammed, S.; Mohebi, F.; Moitra, M.; Mokdad, A.H.; Molokhia, M.; Monasta, L.; Moodley, Y.; Moosazadeh, M.; Moradi, G.; Moradi-Lakeh, M.; Moradinazar, M.; Moraga, P.; Morawska, L.; Moreno Velásquez, I.; Morgado-Da-Costa, J.; Morrison, S.D.; Moschos, M.M.; Mountjoy-Venning, W.C.; Mousavi, S.M.; Mruts, K.B.; Muche, A.A.; Muchie, K.F.; Mueller, U.O.; Muhammed, O.S.; Mukhopadhyay, S.; Muller, K.; Mumford, J.E.; Murhekar, M.; Musa, J.; Musa, K.I.; Mustafa, G.; Nabhan, A.F.; Nagata, C.; Naghavi, M.; Naheed, A.; Nahvijou, A.; Naik, G.; Naik, N.; Najafi, F.; Naldi, L.; Nam, H.S.; Nangia, V.; Nansseu, J.R.; Nascimento, B.R.; Natarajan, G.; Neamati, N.; Negoi, I.; Negoi, R.I.; Neupane, S.; Newton, C.R.J.; Ngunjiri, J.W.; Nguyen, A.Q.; Nguyen, H.T.; Nguyen, H.L.T.; Nguyen, H.T.; Nguyen, L.H.; Nguyen, M.; Nguyen, N.B.; Nguyen, S.H.; Nichols, E.; Ningrum, D.N.A.; Nixon, M.R.; Nolutshungu, N.; Nomura, S.; Norheim, O.F.; Noroozi, M.; Norrving, B.; Noubiap, J.J.; Nouri, H.R.; Nourollahpour Shiadeh, M.; Nowroozi, M.R.; Nsoesie, E.O.; Nyasulu, P.S.; Odell, C.M.; Ofori-Asenso, R.; Ogbo, F.A.; Oh, I-H.; Oladimeji, O.; Olagunju, A.T.; Olagunju, T.O.; Olivares, P.R.; Olsen, H.E.; Olusanya, B.O.; Ong, K.L.; Ong, S.K.; Oren, E.; Ortiz, A.; Ota, E.; Otstavnov, S.S.; Øverland, S.; Owolabi, M.O.; P A, M.; Pacella, R.; Pakpour, A.H.; Pana, A.; Panda-Jonas, S.; Parisi, A.; Park, E-K.; Parry, C.D.H.; Patel, S.; Pati, S.; Patil, S.T.; Patle, A.; Patton, G.C.; Paturi, V.R.; Paulson, K.R.; Pearce, N.; Pereira, D.M.; Perico, N.; Pesudovs, K.; Pham, H.Q.; Phillips, M.R.; Pigott, D.M.; Pillay, J.D.; Piradov, M.A.; Pirsaheb, M.; Pishgar, F.; Plana-Ripoll, O.; Plass, D.; Polinder, S.; Popova, S.; Postma, M.J.; Pourshams, A.; Poustchi, H.; Prabhakaran, D.; Prakash, S.; Prakash, V.; Purcell, C.A.; Purwar, M.B.; Qorbani, M.; Quistberg, D.A.; Radfar, A.; Rafay, A.; Rafiei, A.; Rahim, F.; Rahimi, K.; Rahimi-Movaghar, A.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M.H.; Rahman, M.A.; Rahman, S.U.; Rai, R.K.; Rajati, F.; Ram, U.; Ranjan, P.; Ranta, A.; Rao, P.C.; Rawaf, D.L.; Rawaf, S.; Reddy, K.S.; Reiner, R.C.; Reinig, N.; Reitsma, M.B.; Remuzzi, G.; Renzaho, A.M.N.; Resnikoff, S.; Rezaei, S.; Rezai, M.S.; Ribeiro, A.L.P.; Roberts, N.L.S.; Robinson, S.R.; Roever, L.; Ronfani, L.; Roshandel, G.; Rostami, A.; Roth, G.A.; Roy, A.; Rubagotti, E.; Sachdev, P.S.; Sadat, N.; Saddik, B.; Sadeghi, E.; Saeedi Moghaddam, S.; Safari, H.; Safari, Y.; Safari-Faramani, R.; Safdarian, M.; Safi, S.; Safiri, S.; Sagar, R.; Sahebkar, A.; Sahraian, M.A.; Sajadi, H.S.; Salam, N.; Salama, J.S.; Salamati, P.; Saleem, K.; Saleem, Z.; Salimi, Y.; Salomon, J.A.; Salvi, S.S.; Salz, I.; Samy, A.M.; Sanabria, J.; Sang, Y.; Santomauro, D.F.; Santos, I.S.; Santos, J.V.; Santric Milicevic, M.M.; Sao Jose, B.P.; Sardana, M.; Sarker, A.R.; Sarrafzadegan, N.; Sartorius, B.; Sarvi, S.; Sathian, B.; Satpathy, M.; Sawant, A.R.; Sawhney, M.; Saxena, S.; Saylan, M.; Schaeffner, E.; Schmidt, M.I.; Schneider, I.J.C.; Schöttker, B.; Schwebel, D.C.; Schwendicke, F.; Scott, J.G.; Sekerija, M.; Sepanlou, S.G.; Serván-Mori, E.; Seyedmousavi, S.; Shabaninejad, H.; Shafieesabet, A.; Shahbazi, M.; Shaheen, A.A.; Shaikh, M.A.; Shams-Beyranvand, M.; Shamsi, M.; Shamsizadeh, M.; Sharafi, H.; Sharafi, K.; Sharif, M.; Sharif-Alhoseini, M.; Sharma, M.; Sharma, R.; She, J.; Sheikh, A.; Shi, P.; Shibuya, K.; Shigematsu, M.; Shiri, R.; Shirkoohi, R.; Shishani, K.; Shiue, I.; Shokraneh, F.; Shoman, H.; Shrime, M.G.; Si, S.; Siabani, S.; Siddiqi, T.J.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silva, J.P.; Silveira, D.G.A.; Singam, N.S.V.; Singh, J.A.; Singh, N.P.; Singh, V.; Sinha, D.N.; Skiadaresi, E.; Slepak, E.L.N.; Sliwa, K.; Smith, D.L.; Smith, M.; Soares Filho, A.M.; Sobaih, B.H.; Sobhani, S.; Sobngwi, E.; Soneji, S.S.; Soofi, M.; Soosaraei, M.; Sorensen, R.J.D.; Soriano, J.B.; Soyiri, I.N.; Sposato, L.A.; Sreeramareddy, C.T.; Srinivasan, V.; Stanaway, J.D.; Stein, D.J.; Steiner, C.; Steiner, T.J.; Stokes, M.A.; Stovner, L.J.; Subart, M.L.; Sudaryanto, A.; Sufiyan, M.B.; Sunguya, B.F.; Sur, P.J.; Sutradhar, I.; Sykes, B.L.; Sylte, D.O.; Tabarés-Seisdedos, R.; Tadakamadla, S.K.; Tadesse, B.T.; Tandon, N.; Tassew, S.G.; Tavakkoli, M.; Taveira, N.; Taylor, H.R.; Tehrani-Banihashemi, A.; Tekalign, T.G.; Tekelemedhin, S.W.; Tekle, M.G.; Temesgen, H.; Temsah, M-H.; Temsah, O.; Terkawi, A.S.; Teweldemedhin, M.; Thankappan, K.R.; Thomas, N.; Tilahun, B.; To, Q.G.; Tonelli, M.; Topor-Madry, R.; Topouzis, F.; Torre, A.E.; Tortajada-Girbés, M.; Touvier, M.; Tovani-Palone, M.R.; Towbin, J.A.; Tran, B.X.; Tran, K.B.; Troeger, C.E.; Truelsen, T.C.; Tsilimbaris, M.K.; Tsoi, D.; Tudor Car, L.; Tuzcu, E.M.; Ukwaja, K.N.; Ullah, I.; Undurraga, E.A.; Unutzer, J.; Updike, R.L.; Usman, M.S.; Uthman, O.A.; Vaduganathan, M.; Vaezi, A.; Valdez, P.R.; Varughese, S.; Vasankari, T.J.; Venketasubramanian, N.; Villafaina, S.; Violante, F.S.; Vladimirov, S.K.; Vlassov, V.; Vollset, S.E.; Vosoughi, K.; Vujcic, I.S.; Wagnew, F.S.; Waheed, Y.; Waller, S.G.; Wang, Y.; Wang, Y-P.; Weiderpass, E.; Weintraub, R.G.; Weiss, D.J.; Weldegebreal, F.; Weldegwergs, K.G.; Werdecker, A.; West, T.E.; Whiteford, H.A.; Widecka, J.; Wijeratne, T.; Wilner, L.B.; Wilson, S.; Winkler, A.S.; Wiyeh, A.B.; Wiysonge, C.S.; Wolfe, C.D.A.; Woolf, A.D.; Wu, S.; Wu, Y-C.; Wyper, G.M.A.; Xavier, D.; Xu, G.; Yadgir, S.; Yadollahpour, A.; Yahyazadeh Jabbari, S.H.; Yamada, T.; Yan, L.L.; Yano, Y.; Yaseri, M.; Yasin, Y.J.; Yeshaneh, A.; Yimer, E.M.; Yip, P.; Yisma, E.; Yonemoto, N.; Yoon, S-J.; Yotebieng, M.; Younis, M.Z.; Yousefifard, M.; Yu, C.; Zadnik, V.; Zaidi, Z.; Zaman, S.B.; Zamani, M.; Zare, Z.; Zeleke, A.J.; Zenebe, Z.M.; Zhang, K.; Zhao, Z.; Zhou, M.; Zodpey, S.; Zucker, I.; Vos, T.; Murray, C.J.L. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159), 1789-1858.
[http://dx.doi.org/10.1016/S0140-6736(18)32279-7] [PMID: 30496104]

GBD 2017: a fragile world. Lancet, 2018, 392(10159), 1683.
[http://dx.doi.org/10.1016/S0140-6736(18)32858-7] [PMID: 30415747]

Santomauro, D.F.; Mantilla, H.A.M.; Shadid, J.; Zheng, P.; Ashbaugh, C.; Pigott, D.M.; Abbafati, C.; Adolph, C.; Amlag, J.O.; Aravkin, A.Y.; Bang-Jensen, B.L.; Bertolacci, G.J.; Bloom, S.S.; Castellano, R.; Castro, E.; Chakrabarti, S.; Chattopadhyay, J.; Cogen, R.M.; Collins, J.K.; Dai, X.; Dangel, W.J.; Dapper, C.; Deen, A.; Erickson, M.; Ewald, S.B.; Flaxman, A.D.; Frostad, J.J.; Fullman, N.; Giles, J.R.; Giref, A.Z.; Guo, G.; He, J.; Helak, M.; Hulland, E.N.; Idrisov, B.; Lindstrom, A.; Linebarger, E.; Lotufo, P.A.; Lozano, R.; Magistro, B.; Malta, D.C.; Månsson, J.C.; Marinho, F.; Mokdad, A.H.; Monasta, L.; Naik, P.; Nomura, S.; O’Halloran, J.K.; Ostroff, S.M.; Pasovic, M.; Penberthy, L.; Reiner, R.C., Jr; Reinke, G.; Ribeiro, A.L.P.; Sholokhov, A.; Sorensen, R.J.D.; Varavikova, E.; Vo, A.T.; Walcott, R.; Watson, S.; Wiysonge, C.S.; Zigler, B.; Hay, S.I.; Vos, T.; Murray, C.J.L.; Whiteford, H.A.; Ferrari, A.J. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet, 2021, 398(10312), 1700-1712.
[http://dx.doi.org/10.1016/S0140-6736(21)02143-7] [PMID: 34634250]

Malhi, G.S.; Mann, J.J. Depression. Lancet, 2018, 392(10161), 2299-2312.
[http://dx.doi.org/10.1016/S0140-6736(18)31948-2] [PMID: 30396512]

Beurel, E.; Toups, M.; Nemeroff, C.B. The bidirectional relationship of depression and inflammation: Double trouble. Neuron, 2020, 107(2), 234-256.
[http://dx.doi.org/10.1016/j.neuron.2020.06.002] [PMID: 32553197]

Gartlehner, G.; Wagner, G.; Matyas, N.; Titscher, V.; Greimel, J.; Lux, L.; Gaynes, B.N.; Viswanathan, M.; Patel, S.; Lohr, K.N. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open, 2017, 7(6), e014912.
[http://dx.doi.org/10.1136/bmjopen-2016-014912] [PMID: 28615268]

Schildkraut, J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry, 1965, 122(5), 509-522.
[http://dx.doi.org/10.1176/ajp.122.5.509] [PMID: 5319766]

Dale, E.; Bang-Andersen, B.; Sánchez, C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem. Pharmacol., 2015, 95(2), 81-97.
[http://dx.doi.org/10.1016/j.bcp.2015.03.011] [PMID: 25813654]

Stahl, S.M. Mood Disorders and Antidepressants: Stahl’s Essential Psychopharmacology; Cambridge university press, 2013.

Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry, 2006, 163(11), 1905-1917.
[http://dx.doi.org/10.1176/ajp.2006.163.11.1905] [PMID: 17074942]

Su, W.J.; Cao, Z.Y.; Jiang, C.L. Blocking the trigger: An integrative view on the anti-inflammatory therapy of depression. Brain Behav. Immun., 2019, 82, 10-12.
[http://dx.doi.org/10.1016/j.bbi.2019.09.002] [PMID: 31493446]

Gartlehner, G.; Thieda, P.; Hansen, R.A.; Gaynes, B.N.; DeVeaugh-Geiss, A.; Krebs, E.E.; Lohr, K.N. Comparative risk for harms of second-generation antidepressants: A systematic review and meta-analysis. Drug Saf., 2008, 31(10), 851-865.
[http://dx.doi.org/10.2165/00002018-200831100-00004] [PMID: 18759509]

Ogłodek, E.; Szota, A.; Just, M.; Moś D.; Araszkiewicz, A. The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol. Rep., 2014, 66(5), 776-781.
[http://dx.doi.org/10.1016/j.pharep.2014.04.009] [PMID: 25149980]

Numakawa, T.; Richards, M.; Nakajima, S.; Adachi, N.; Furuta, M.; Odaka, H.; Kunugi, H. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. Front. Psychiatry, 2014, 5, 136.
[http://dx.doi.org/10.3389/fpsyt.2014.00136] [PMID: 25309465]

Verduijn, J.; Milaneschi, Y.; Schoevers, R.A.; van Hemert, A.M.; Beekman, A.T.F.; Penninx, B.W.J.H. Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression. Transl. Psychiatry, 2015, 5(9), e649.
[http://dx.doi.org/10.1038/tp.2015.137] [PMID: 26418277]

Koo, J.W.; Wohleb, E.S. How stress shapes neuroimmune function: Implications for the neurobiology of psychiatric disorders. Biol. Psychiatry, 2021, 90(2), 74-84.
[http://dx.doi.org/10.1016/j.biopsych.2020.11.007] [PMID: 33485589]

Ishikawa, Y.; Furuyashiki, T. The impact of stress on immune systems and its relevance to mental illness. Neurosci. Res., 2022, 175, 16-24.
[http://dx.doi.org/10.1016/j.neures.2021.09.005] [PMID: 34606943]

Tafet, G.E.; Nemeroff, C.B. The links between stress and depression: Psychoneuroendocrinological, genetic, and environmental interactions. J. Neuropsychiatry Clin. Neurosci., 2016, 28(2), 77-88.
[http://dx.doi.org/10.1176/appi.neuropsych.15030053] [PMID: 26548654]

Smith, R.S. The macrophage theory of depression. Med. Hypotheses, 1991, 35(4), 298-306.
[http://dx.doi.org/10.1016/0306-9877(91)90272-Z] [PMID: 1943879]

Pape, K.; Tamouza, R.; Leboyer, M.; Zipp, F. Immunoneuropsychiatry — novel perspectives on brain disorders. Nat. Rev. Neurol., 2019, 15(6), 317-328.
[http://dx.doi.org/10.1038/s41582-019-0174-4] [PMID: 30988501]

Carlsson, A.; Corrodi, H.; Fuxe, K.; Hökfelt, T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur. J. Pharmacol., 1969, 5(4), 357-366.
[http://dx.doi.org/10.1016/0014-2999(69)90113-7] [PMID: 5786359]

Cipriani, A.; Furukawa, T.A.; Salanti, G.; Chaimani, A.; Atkinson, L.Z.; Ogawa, Y.; Leucht, S.; Ruhe, H.G.; Turner, E.H.; Higgins, J.P.T.; Egger, M.; Takeshima, N.; Hayasaka, Y.; Imai, H.; Shinohara, K.; Tajika, A.; Ioannidis, J.P.A.; Geddes, J.R. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet, 2018, 391(10128), 1357-1366.
[http://dx.doi.org/10.1016/S0140-6736(17)32802-7] [PMID: 29477251]

Wetsman, N. Inflammatory illness: Why the next wave of antidepressants may target the immune system. Nat. Med., 2017, 23(9), 1009-1011.
[http://dx.doi.org/10.1038/nm0917-1009] [PMID: 28886000]

Hamidpour, R.; Hamidpour, S.; Hamidpour, M.; Shahlari, M. Frankincense (rǔ xiāng; boswellia species): from the selection of traditional applications to the novel phytotherapy for the prevention and treatment of serious diseases. J. Tradit. Complement. Med., 2013, 3(4), 221-226.
[http://dx.doi.org/10.4103/2225-4110.119723] [PMID: 24716181]

Yao, G.; Li, J.; Wang, J.; Liu, S.; Li, X.; Cao, X.; Chen, H.; Xu, Y. Improved resting-state functional dynamics in post-stroke depressive patients after shugan jieyu capsule treatment. Front. Neurosci., 2020, 14, 297.
[http://dx.doi.org/10.3389/fnins.2020.00297] [PMID: 32372901]

Tan, J.; Li, X.; Zhu, Y.; Sullivan, M.A.; Deng, B.; Zhai, X.; Lu, Y. Antidepressant shugan jieyu capsule alters gut microbiota and intestinal microbiome function in rats with chronic unpredictable mild stress -induced depression. Front. Pharmacol., 2022, 13, 828595.
[http://dx.doi.org/10.3389/fphar.2022.828595] [PMID: 35770090]

Miller, J. Antidepressants, part 1: 100 years and counting. Psychiatr. Times, 2017, 34(10), 23-26.

Shitiz, K.; Gupta, S.P. Rauwolfia serpentina; Himalayan Medicinal Plants, 2021.
[http://dx.doi.org/10.1016/B978-0-12-823151-7.00009-X]

Vakil, R.J. Rauwolfia serpentina in the treatment of high blood pressure; a review of the literature. Circulation, 1955, 12(2), 220-229.
[http://dx.doi.org/10.1161/01.CIR.12.2.220] [PMID: 13240803]

Quetsch, R.M.; Achor, R.W.P.; Litin, E.M.; Faucett, R.L. Depressive reactions in hypertensive patients; a comparison of those treated with Rauwolfia and those receiving no specific antihypertensive treatment. Circulation, 1959, 19(3), 366-375.
[http://dx.doi.org/10.1161/01.CIR.19.3.366] [PMID: 13629798]

Robitzek, E.H.; Selikoff, I.J. Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report. Am. Rev. Tuberc., 1952, 65(4), 402-428.
[PMID: 14903507]

Brown, W.A.; Rosdolsky, M. The clinical discovery of imipramine. Am. J. Psychiatry, 2015, 172(5), 426-429.
[http://dx.doi.org/10.1176/appi.ajp.2015.14101336] [PMID: 25930134]

Axelrod, J.; Whitby, L.G.; Hertting, G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science, 1961, 133(3450), 383-384.
[http://dx.doi.org/10.1126/science.133.3450.383] [PMID: 13685337]

Fleming, A.; Eisendrath, S. Depression. In: Encyclopedia of the Neurological Sciences; Aminoff, M.J.; Daroff, R.B., Eds.; Academic Press: New York, 2003; pp. 853-860.
[http://dx.doi.org/10.1016/B0-12-226870-9/01067-4]

Harmer, C.J.; Duman, R.S.; Cowen, P.J. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry, 2017, 4(5), 409-418.
[http://dx.doi.org/10.1016/S2215-0366(17)30015-9] [PMID: 28153641]

Bauer, M.; Bschor, T.; Pfennig, A.; Whybrow, P.C.; Angst, J.; Versiani, M.; Möller, H.J.; Bauer, M.; Bschor, T.; Pfennig, A.; Whybrow, P.C.; Angst, J.; Versiani, M.; Möller, H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry, 2007, 8(2), 67-104.
[http://dx.doi.org/10.1080/15622970701227829] [PMID: 17455102]

Cleare, A.; Pariante, C.M.; Young, A.H.; Anderson, I.M.; Christmas, D.; Cowen, P.J.; Dickens, C.; Ferrier, I.N.; Geddes, J.; Gilbody, S.; Haddad, P.M.; Katona, C.; Lewis, G.; Malizia, A.; McAllister-Williams, R.H.; Ramchandani, P.; Scott, J.; Taylor, D.; Uher, R. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J. Psychopharmacol., 2015, 29(5), 459-525.
[http://dx.doi.org/10.1177/0269881115581093] [PMID: 25969470]

Deardorff, W.J.; Grossberg, G.T. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin. Pharmacother., 2014, 15(17), 2525-2542.
[http://dx.doi.org/10.1517/14656566.2014.960842] [PMID: 25224953]

Kent, J.M. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet, 2000, 355(9207), 911-918.
[http://dx.doi.org/10.1016/S0140-6736(99)11381-3] [PMID: 10752718]

Guaiana, G.; Gupta, S.; Chiodo, D.; Davies, S.J.C.; Haederle, K.; Koesters, M. Agomelatine versus other antidepressive agents for major depression. Cochrane Libr., 2013, (12), CD008851.
[http://dx.doi.org/10.1002/14651858.CD008851.pub2] [PMID: 24343836]

Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies. BMJ, 2014, 348, g1888.
[http://dx.doi.org/10.1136/bmj.g1888]

Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47(4), 351-354.
[http://dx.doi.org/10.1016/S0006-3223(99)00230-9] [PMID: 10686270]

Ramadan, A.M.; Mansour, I.A. Could ketamine be the answer to treating treatment-resistant major depressive disorder? Gen. Psychiatr., 2020, 33(5), e100227.
[http://dx.doi.org/10.1136/gpsych-2020-100227] [PMID: 32875273]

Mcdonald, E.M.; Mann, A.H.; Thomas, H.C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet, 1987, 330(8569), 1175-1178.
[http://dx.doi.org/10.1016/S0140-6736(87)91319-5] [PMID: 2890808]

Niiranen, A.; Laaksonen, R. livanainen, M.; Mattson, K.; Färkkilä, M.; Cantell, K. Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr. Scand., 1988, 78(5), 622-626.
[http://dx.doi.org/10.1111/j.1600-0447.1988.tb06395.x] [PMID: 3232542]

Maes, M.; Smith, R.; Simon, S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology, 1995, 20(2), 111-116.
[http://dx.doi.org/10.1016/0306-4530(94)00066-J] [PMID: 7899532]

Dantzer, R.; O’Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9(1), 46-56.
[http://dx.doi.org/10.1038/nrn2297] [PMID: 18073775]

Kim, Y.K.; Na, K.S.; Myint, A.M.; Leonard, B.E. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 64, 277-284.
[http://dx.doi.org/10.1016/j.pnpbp.2015.06.008] [PMID: 26111720]

Petralia, M.C.; Mazzon, E.; Fagone, P.; Basile, M.S.; Lenzo, V.; Quattropani, M.C.; Di Nuovo, S.; Bendtzen, K.; Nicoletti, F. The cytokine network in the pathogenesis of major depressive disorder. Close to translation? Autoimmun. Rev., 2020, 19(5), 102504.
[http://dx.doi.org/10.1016/j.autrev.2020.102504] [PMID: 32173514]

Raison, C.L.; Capuron, L.; Miller, A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol., 2006, 27(1), 24-31.
[http://dx.doi.org/10.1016/j.it.2005.11.006] [PMID: 16316783]

Su, W.J.; Cao, Z.Y.; Jiang, C.L. Inflammatory mechanism of depression and its new strategy for diagnosis and treatment. Sheng Li Xue Bao, 2017, 69(5), 715-722.
[PMID: 29063119]

Young, J.J.; Bruno, D.; Pomara, N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J. Affect. Disord., 2014, 169, 15-20.
[http://dx.doi.org/10.1016/j.jad.2014.07.032] [PMID: 25128861]

Howren, M.B.; Lamkin, D.M.; Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med., 2009, 71(2), 171-186.
[http://dx.doi.org/10.1097/PSY.0b013e3181907c1b] [PMID: 19188531]

Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry, 2010, 67(5), 446-457.
[http://dx.doi.org/10.1016/j.biopsych.2009.09.033] [PMID: 20015486]

Köhler, C.A.; Freitas, T.H.; Maes, M.; de Andrade, N.Q.; Liu, C.S.; Fernandes, B.S.; Stubbs, B.; Solmi, M.; Veronese, N.; Herrmann, N.; Raison, C.L.; Miller, B.J.; Lanctôt, K.L.; Carvalho, A.F. Peripheral cytokine and chemokine alterations in depression: A meta-analysis of 82 studies. Acta Psychiatr. Scand., 2017, 135(5), 373-387.
[http://dx.doi.org/10.1111/acps.12698] [PMID: 28122130]

Enache, D.; Pariante, C.M.; Mondelli, V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav. Immun., 2019, 81, 24-40.
[http://dx.doi.org/10.1016/j.bbi.2019.06.015] [PMID: 31195092]

Matcham, F.; Rayner, L.; Steer, S.; Hotopf, M. The prevalence of depression in rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology, 2013, 52(12), 2136-2148.
[http://dx.doi.org/10.1093/rheumatology/ket169] [PMID: 24003249]

Barberio, B.; Zamani, M.; Black, C.J.; Savarino, E.V.; Ford, A.C. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2021, 6(5), 359-370.
[http://dx.doi.org/10.1016/S2468-1253(21)00014-5] [PMID: 33721557]

Dowlatshahi, E.A.; Wakkee, M.; Arends, L.R.; Nijsten, T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J. Invest. Dermatol., 2014, 134(6), 1542-1551.
[http://dx.doi.org/10.1038/jid.2013.508] [PMID: 24284419]

Moustafa, A.T.; Moazzami, M.; Engel, L.; Bangert, E.; Hassanein, M.; Marzouk, S.; Kravtsenyuk, M.; Fung, W.; Eder, L.; Su, J.; Wither, J.E.; Touma, Z. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Semin. Arthritis Rheum., 2020, 50(1), 84-94.
[http://dx.doi.org/10.1016/j.semarthrit.2019.06.017] [PMID: 31303437]

Fotopoulos, A.; Petrikis, P.; Sioka, C. Depression and coronary artery disease. Psychiatr. Danub., 2021, 33(1), 73.
[PMID: 33857047]

McFarland, D.C.; Doherty, M.; Atkinson, T.M.; O’Hanlon, R.; Breitbart, W.; Nelson, C.J.; Miller, A.H. Cancer‐related inflammation and depressive symptoms: Systematic review and meta‐analysis. Cancer, 2022, 128(13), 2504-2519.
[http://dx.doi.org/10.1002/cncr.34193] [PMID: 35417925]

Gold, S.M.; Köhler-Forsberg, O.; Moss-Morris, R.; Mehnert, A.; Miranda, J.J.; Bullinger, M.; Steptoe, A.; Whooley, M.A.; Otte, C. Comorbid depression in medical diseases. Nat. Rev. Dis. Primers, 2020, 6(1), 69.
[http://dx.doi.org/10.1038/s41572-020-0200-2] [PMID: 32820163]

Schaefer, M.; Engelbrechta, M.A.; Gut, O.; Fiebich, B.L.; Bauer, J.; Schmidt, F.; Grunze, H.; Lieb, K. Interferon alpha (IFNα) and psychiatric syndromes. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(4), 731-746.
[http://dx.doi.org/10.1016/S0278-5846(01)00324-4] [PMID: 12188106]

Benson, S.; Engler, H.; Wegner, A.; Rebernik, L.; Spreitzer, I.; Schedlowski, M.; Elsenbruch, S. What makes you feel sick after inflammation? predictors of acute and persisting physical sickness symptoms induced by experimental endotoxemia. Clin. Pharmacol. Ther., 2017, 102(1), 141-151.
[http://dx.doi.org/10.1002/cpt.618] [PMID: 28074475]

Kim, Y.K.; Na, K.S.; Shin, K.H.; Jung, H.Y.; Choi, S.H.; Kim, J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(5), 1044-1053.
[http://dx.doi.org/10.1016/j.pnpbp.2007.03.004] [PMID: 17433516]

Wu, H.; Denna, T.H.; Storkersen, J.N.; Gerriets, V.A. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol. Res., 2019, 140, 100-114.
[http://dx.doi.org/10.1016/j.phrs.2018.06.015] [PMID: 29953943]

Wang, L.; Wang, R.; Liu, L.; Qiao, D.; Baldwin, D.S.; Hou, R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. Brain Behav. Immun., 2019, 79, 24-38.
[http://dx.doi.org/10.1016/j.bbi.2019.02.021] [PMID: 30797959]

Dionisie, V.; Filip, G.A.; Manea, M.C.; Manea, M.; Riga, S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology, 2021, 29(1), 75-90.
[http://dx.doi.org/10.1007/s10787-020-00777-5] [PMID: 33164143]

O’Brien, S.M.; Scully, P.; Fitzgerald, P.; Scott, L.V.; Dinan, T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res., 2007, 41(3-4), 326-331.
[http://dx.doi.org/10.1016/j.jpsychires.2006.05.013] [PMID: 16870211]

Strawbridge, R.; Marwood, L.; King, S.; Young, A.H.; Pariante, C.M.; Colasanti, A.; Cleare, A.J. Inflammatory proteins and clinical response to psychological therapy in patients with depression: An exploratory study. J. Clin. Med., 2020, 9(12), 3918.
[http://dx.doi.org/10.3390/jcm9123918] [PMID: 33276697]

Suarez, E.C.; Krishnan, R.R.; Lewis, J.G. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom. Med., 2003, 65(3), 362-368.
[http://dx.doi.org/10.1097/01.PSY.0000035719.79068.2B] [PMID: 12764208]

Kappelmann, N.; Lewis, G.; Dantzer, R.; Jones, P.B.; Khandaker, G.M. Antidepressant activity of anti-cytokine treatment: A systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry, 2018, 23(2), 335-343.
[http://dx.doi.org/10.1038/mp.2016.167] [PMID: 27752078]

Rethorst, C.D.; Toups, M.S.; Greer, T.L.; Nakonezny, P.A.; Carmody, T.J.; Grannemann, B.D.; Huebinger, R.M.; Barber, R.C.; Trivedi, M.H. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol. Psychiatry, 2013, 18(10), 1119-1124.
[http://dx.doi.org/10.1038/mp.2012.125] [PMID: 22925832]

O’Donovan, A.; Rush, G.; Hoatam, G.; Hughes, B.M.; McCrohan, A.; Kelleher, C.; O’Farrelly, C.; Malone, K.M. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress. Anxiety, 2013, 30(4), 307-314.
[http://dx.doi.org/10.1002/da.22087] [PMID: 23504697]

Black, C.; Miller, B.J. Meta-analysis of cytokines and chemokines in suicidality: Distinguishing suicidal versus nonsuicidal patients. Biol. Psychiatry, 2015, 78(1), 28-37.
[http://dx.doi.org/10.1016/j.biopsych.2014.10.014] [PMID: 25541493]

Fazel, S.; Runeson, B. Suicide. N. Engl. J. Med., 2020, 382(3), 266-274.
[http://dx.doi.org/10.1056/NEJMra1902944] [PMID: 31940700]

Yan, W.J.; Jiang, C.L.; Su, W.J. Life in the flame: Inflammation sounds the alarm for suicide risk. Brain, Behavior, & Immunity - Health, 2021, 14, 100250.
[http://dx.doi.org/10.1016/j.bbih.2021.100250] [PMID: 34589761]

Franklin, T.C.; Xu, C.; Duman, R.S. Depression and sterile inflammation: Essential role of danger associated molecular patterns. Brain Behav. Immun., 2018, 72, 2-13.
[http://dx.doi.org/10.1016/j.bbi.2017.10.025] [PMID: 29102801]

Chen, G.Y.; Nuñez, G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol., 2010, 10(12), 826-837.
[http://dx.doi.org/10.1038/nri2873] [PMID: 21088683]

Perrin, A.J.; Horowitz, M.A.; Roelofs, J.; Zunszain, P.A.; Pariante, C.M. Glucocorticoid resistance: Is it a requisite for increased cytokine production in depression? a systematic review and meta-analysis. Front. Psychiatry, 2019, 10, 423.
[http://dx.doi.org/10.3389/fpsyt.2019.00423] [PMID: 31316402]

Chen, S.; Zhang, Y.; Yuan, Y. The combination of serum BDNF, cortisol and IFN-gamma can assist the diagnosis of major depressive disorder. Neuropsychiatr. Dis. Treat., 2021, 17, 2819-2829.
[http://dx.doi.org/10.2147/NDT.S322078] [PMID: 34471356]

Amasi-Hartoonian, N.; Sforzini, L.; Cattaneo, A.; Pariante, C.M. Cause or consequence? Understanding the role of cortisol in the increased inflammation observed in depression. Curr. Opin. Endocr. Metab. Res., 2022, 24, 100356.
[http://dx.doi.org/10.1016/j.coemr.2022.100356] [PMID: 35634363]

Pace, T.W.W.; Miller, A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci., 2009, 1179(1), 86-105.
[http://dx.doi.org/10.1111/j.1749-6632.2009.04984.x] [PMID: 19906234]

Lauer, C.J.; Schreiber, W.; Modell, S.; Holsboer, F.; Krieg, J.C. The Munich vulnerability study on affective disorders: overview of the cross-sectional observations at index investigation. J. Psychiatr. Res., 1998, 32(6), 393-401.
[http://dx.doi.org/10.1016/S0022-3956(98)00026-0] [PMID: 9844956]

Kim, Y.K.; Won, E. The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behav. Brain Res., 2017, 329, 6-11.
[http://dx.doi.org/10.1016/j.bbr.2017.04.020] [PMID: 28442354]

Maes, M.; Song, C.; Lin, A.; De Jongh, R.; Van Gastel, A.; Kenis, G.; Bosmans, E.; De Meester, I.; Benoy, I.; Neels, H.; Demedts, P.; Janca, A.; Scharpé, S.; Smith, R.S. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine, 1998, 10(4), 313-318.
[http://dx.doi.org/10.1006/cyto.1997.0290] [PMID: 9617578]

Mittwoch-Jaffe, T.; Shalit, F.; Srendi, B.; Yehuda, S. Modification of cytokine secretion following mild emotional stimuli. Neuroreport, 1995, 6(5), 789-792.
[http://dx.doi.org/10.1097/00001756-199503270-00021] [PMID: 7605950]

Dobbin, J.P.; Harth, M.; McCain, G.A.; Martin, R.A.; Cousin, K. Cytokine production and lymphocyte transformation during stress. Brain Behav. Immun., 1991, 5(4), 339-348.
[http://dx.doi.org/10.1016/0889-1591(91)90029-A] [PMID: 1777728]

Su, W.J.; Zhang, T.; Jiang, C.L.; Wang, W. Clemastine alleviates depressive-like behavior through reversing the imbalance of microglia-related pro-inflammatory state in mouse hippocampus. Front. Cell. Neurosci., 2018, 12, 412.
[http://dx.doi.org/10.3389/fncel.2018.00412] [PMID: 30483062]

Berk, M.; Williams, L.J.; Jacka, F.N.; O’Neil, A.; Pasco, J.A.; Moylan, S.; Allen, N.B.; Stuart, A.L.; Hayley, A.C.; Byrne, M.L.; Maes, M. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med., 2013, 11(1), 200.
[http://dx.doi.org/10.1186/1741-7015-11-200] [PMID: 24228900]

Rider, P.; Voronov, E.; Dinarello, C.A.; Apte, R.N.; Cohen, I. Alarmins: Feel the stress. J. Immunol., 2017, 198(4), 1395-1402.
[http://dx.doi.org/10.4049/jimmunol.1601342] [PMID: 28167650]

Samir, P.; Kesavardhana, S.; Patmore, D.M.; Gingras, S.; Malireddi, R.K.S.; Karki, R.; Guy, C.S.; Briard, B.; Place, D.E.; Bhattacharya, A.; Sharma, B.R.; Nourse, A.; King, S.V.; Pitre, A.; Burton, A.R.; Pelletier, S.; Gilbertson, R.J.; Kanneganti, T.D. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature, 2019, 573(7775), 590-594.
[http://dx.doi.org/10.1038/s41586-019-1551-2] [PMID: 31511697]

Troubat, R.; Barone, P.; Leman, S.; Desmidt, T.; Cressant, A.; Atanasova, B.; Brizard, B.; El Hage, W.; Surget, A.; Belzung, C.; Camus, V. Neuroinflammation and depression: A review. Eur. J. Neurosci., 2021, 53(1), 151-171.
[http://dx.doi.org/10.1111/ejn.14720] [PMID: 32150310]

Blatteis, C.M.; Bealer, S.L.; Hunter, W.S.; Llanos, J-Q.; Ahokas, R.A.; Mashburn, T.A., Jr Suppression of fever after lesions of the anteroventral third ventricle in guinea pigs. Brain Res. Bull., 1983, 11(5), 519-526.
[http://dx.doi.org/10.1016/0361-9230(83)90124-7] [PMID: 6365250]

Hsuchou, H.; Kastin, A.J.; Mishra, P.K.; Pan, W. C-reactive protein increases BBB permeability: Implications for obesity and neuroinflammation. Cell. Physiol. Biochem., 2012, 30(5), 1109-1119.
[http://dx.doi.org/10.1159/000343302] [PMID: 23018453]

Banks, W.A.; Kastin, A.J.; Durham, D.A. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res. Bull., 1989, 23(6), 433-437.
[http://dx.doi.org/10.1016/0361-9230(89)90185-8] [PMID: 2611685]

Pan, W.; Kastin, A.J. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp. Neurol., 2002, 174(2), 193-200.
[http://dx.doi.org/10.1006/exnr.2002.7871] [PMID: 11922661]

Watkins, L.R.; Goehler, L.E.; Relton, J.K.; Tartaglia, N.; Silbert, L.; Martin, D.; Maier, S.F. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immune-brain communication. Neurosci. Lett., 1995, 183(1-2), 27-31.
[http://dx.doi.org/10.1016/0304-3940(94)11105-R] [PMID: 7746479]

Verma, S.; Nakaoke, R.; Dohgu, S.; Banks, W.A. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav. Immun., 2006, 20(5), 449-455.
[http://dx.doi.org/10.1016/j.bbi.2005.10.005] [PMID: 16309883]

Harry, G.J.; Kraft, A.D. Neuroinflammation and microglia: Considerations and approaches for neurotoxicity assessment. Expert Opin. Drug Metab. Toxicol., 2008, 4(10), 1265-1277.
[http://dx.doi.org/10.1517/17425255.4.10.1265] [PMID: 18798697]

D’Mello, C.; Le, T.; Swain, M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci., 2009, 29(7), 2089-2102.
[http://dx.doi.org/10.1523/JNEUROSCI.3567-08.2009] [PMID: 19228962]

Peraçoli, M.; Kurokawa, C.S.; Calvi, S.A.; Mendes, R.P.; Pereira, P.C.; Marques, S.A.; Soares, A.M. Production of pro- and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes Infect., 2003, 5(5), 413-418.
[http://dx.doi.org/10.1016/S1286-4579(03)00040-6] [PMID: 12737997]

Gritti, D.; Delvecchio, G.; Ferro, A.; Bressi, C.; Brambilla, P. Neuroinflammation in major depressive disorder: A review of pet imaging studies examining the 18-kDa translocator protein. J. Affect. Disord., 2021, 292, 642-651.
[http://dx.doi.org/10.1016/j.jad.2021.06.001] [PMID: 34153835]

Köhler-Forsberg, O.N.; Lydholm, C.; Hjorthøj, C.; Nordentoft, M.; Mors, O.; Benros, M.E. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr. Scand., 2019, 139(5), 404-419.
[http://dx.doi.org/10.1111/acps.13016] [PMID: 30834514]

Shim, H. One target, different effects: A comparison of distinct therapeutic antibodies against the same targets. Exp. Mol. Med., 2011, 43(10), 539-549.
[http://dx.doi.org/10.3858/emm.2011.43.10.063] [PMID: 21811090]

Zhao, S.; Chadwick, L.; Mysler, E.; Moots, R.J. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr. Rheumatol. Rep., 2018, 20(10), 57.
[http://dx.doi.org/10.1007/s11926-018-0769-6] [PMID: 30094742]

Cvetković R.S.; Scott, L.J. Adalimumab: A review of its use in adult patients with rheumatoid arthritis. BioDrugs, 2006, 20(5), 293-311.
[http://dx.doi.org/10.2165/00063030-200620050-00005] [PMID: 17025376]

Loftus, E.V.; Feagan, B.G.; Colombel, J.F.; Rubin, D.T.; Wu, E.Q.; Yu, A.P.; Pollack, P.F.; Chao, J.; Mulani, P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: Patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol., 2008, 103(12), 3132-3141.
[http://dx.doi.org/10.1111/j.1572-0241.2008.02175.x] [PMID: 18853973]

Menter, A.; Augustin, M.; Signorovitch, J.; Yu, A.P.; Wu, E.Q.; Gupta, S.R.; Bao, Y.; Mulani, P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial. J. Am. Acad. Dermatol., 2010, 62(5), 812-818.
[http://dx.doi.org/10.1016/j.jaad.2009.07.022] [PMID: 20219265]

Lim, S.H.; Kim, K.; Choi, C.I. Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis. J. Pers. Med., 2022, 12(8), 1265.
[http://dx.doi.org/10.3390/jpm12081265] [PMID: 36013214]

Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41.
[http://dx.doi.org/10.1001/2013.jamapsychiatry.4] [PMID: 22945416]

Weinberger, J.F.; Raison, C.L.; Rye, D.B.; Montague, A.R.; Woolwine, B.J.; Felger, J.C.; Haroon, E.; Miller, A.H. Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav. Immun., 2015, 47, 193-200.
[http://dx.doi.org/10.1016/j.bbi.2014.12.016] [PMID: 25529904]

Webers, C.; Stolwijk, C.; Schiepers, O.; Schoonbrood, T.; van Tubergen, A.; Landewé, R.; van der Heijde, D.; Boonen, A. Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: An ancillary study to a randomized controlled trial (ASSERT). Arthritis Res. Ther., 2020, 22(1), 225.
[http://dx.doi.org/10.1186/s13075-020-02305-w] [PMID: 32993799]

Goffe, B.; Cather, J.C. Etanercept: An overview. J. Am. Acad. Dermatol., 2003, 49(S2), 105-111.
[http://dx.doi.org/10.1016/mjd.2003.554] [PMID: 12894133]

Kekow, J.; Moots, R.J.; Emery, P.; Durez, P.; Koenig, A.; Singh, A.; Pedersen, R.; Robertson, D.; Freundlich, B.; Sato, R. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann. Rheum. Dis., 2010, 69(1), 222-225.
[http://dx.doi.org/10.1136/ard.2008.102509] [PMID: 19293160]

Tyring, S.; Bagel, J.; Lynde, C.; Klekotka, P.; Thompson, E.H.Z.; Gandra, S.R.; Shi, Y.; Kricorian, G. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: Results from a randomized, double-blind, placebo-controlled study of etanercept. J. Eur. Acad. Dermatol. Venereol., 2013, 27(1), 125-128.
[http://dx.doi.org/10.1111/j.1468-3083.2011.04394.x] [PMID: 22188302]

Sun, Y.; Wang, D.; Salvadore, G.; Hsu, B.; Curran, M.; Casper, C.; Vermeulen, J.; Kent, J.M.; Singh, J.; Drevets, W.C.; Wittenberg, G.M.; Chen, G. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman’s disease. Brain Behav. Immun., 2017, 66, 156-164.
[http://dx.doi.org/10.1016/j.bbi.2017.06.014] [PMID: 28676350]

Narazaki, M.; Tanaka, T.; Kishimoto, T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev. Clin. Immunol., 2017, 13(6), 535-551.
[http://dx.doi.org/10.1080/1744666X.2017.1295850] [PMID: 28494214]

Griffiths, C.E.M.; Fava, M.; Miller, A.H.; Russell, J.; Ball, S.G.; Xu, W.; Acharya, N.; Rapaport, M.H. Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: An integrated analysis of three phase 3 clinical studies. Psychother. Psychosom., 2017, 86(5), 260-267.
[http://dx.doi.org/10.1159/000479163] [PMID: 28903122]

Wang, R.; Maksymowych, W.P. Targeting the interleukin-23/interleukin-17 inflammatory pathway: Successes and failures in the treatment of axial spondyloarthritis. Front. Immunol., 2021, 12, 715510.
[http://dx.doi.org/10.3389/fimmu.2021.715510] [PMID: 34539646]

Kim, S.J.; Park, M.Y.; Pak, K.; Han, J.; Kim, G.W.; Kim, H.S.; Ko, H.C.; Kim, M.B.; Kim, B.S. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: An open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18 fluorodeoxyglucose (FDG) positron emission tomography (PET). J. Dermatolog. Treat., 2018, 29(8), 761-768.
[http://dx.doi.org/10.1080/09546634.2018.1466021] [PMID: 29658378]

Simpson, E.L.; Gadkari, A.; Worm, M.; Soong, W.; Blauvelt, A.; Eckert, L.; Wu, R.; Ardeleanu, M.; Graham, N.M.H.; Pirozzi, G.; Sutherland, E.R.; Mastey, V. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J. Am. Acad. Dermatol., 2016, 75(3), 506-515.
[http://dx.doi.org/10.1016/j.jaad.2016.04.054] [PMID: 27268421]

Cork, M.J.; Eckert, L.; Simpson, E.L.; Armstrong, A.; Barbarot, S.; Puig, L.; Girolomoni, G.; de Bruin-Weller, M.; Wollenberg, A.; Kataoka, Y.; Remitz, A.; Beissert, S.; Mastey, V.; Ardeleanu, M.; Chen, Z.; Gadkari, A.; Chao, J. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: Analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J. Dermatolog. Treat., 2020, 31(6), 606-614.
[http://dx.doi.org/10.1080/09546634.2019.1612836] [PMID: 31179791]

Zobdeh, F.; Eremenko, I.I.; Akan, M.A.; Tarasov, V.V.; Chubarev, V.N.; Schiöth, H.B.; Mwinyi, J. Pharmacogenetics and pain treatment with a focus on non-steroidal Anti-Inflammatory Drugs (NSAIDs) and antidepressants: A systematic review. Pharmaceutics, 2022, 14(6), 1190.
[http://dx.doi.org/10.3390/pharmaceutics14061190] [PMID: 35745763]

Ozleyen, A.; Yilmaz, Y.B.; Donmez, S.; Atalay, H.N.; Antika, G.; Tumer, T.B. Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention. J. Cancer Res. Clin. Oncol., 2022, 1-19.
[http://dx.doi.org/10.1007/s00432-022-04187-8] [PMID: 35876951]

Sinniah, A.; Yazid, S.; Flower, R.J. From NSAIDs to Glucocorticoids and Beyond. Cells, 2021, 10(12), 3524.
[http://dx.doi.org/10.3390/cells10123524] [PMID: 34944032]

Flower, R.J. The development of COX2 inhibitors. Nat. Rev. Drug Discov., 2003, 2(3), 179-191.
[http://dx.doi.org/10.1038/nrd1034] [PMID: 12612644]

Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; Möller, H-J.; Arolt, V.; Riedel, M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry, 2006, 11(7), 680-684.
[http://dx.doi.org/10.1038/sj.mp.4001805] [PMID: 16491133]

Akhondzadeh, S.; Jafari, S.; Raisi, F.; Nasehi, A.A.; Ghoreishi, A.; Salehi, B.; Mohebbi-Rasa, S.; Raznahan, M.; Kamalipour, A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Depress. Anxiety, 2009, 26(7), 607-611.
[http://dx.doi.org/10.1002/da.20589] [PMID: 19496103]

Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J. Affect. Disord., 2012, 141(2-3), 308-314.
[http://dx.doi.org/10.1016/j.jad.2012.03.033] [PMID: 22516310]

Jafari, S.; Ashrafizadeh, S.G.; Zeinoddini, A.; Rasoulinejad, M.; Entezari, P.; Seddighi, S.; Akhondzadeh, S. Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: A double-blind, placebo-controlled, randomized trial. J. Clin. Pharm. Ther., 2015, 40(4), 441-446.
[http://dx.doi.org/10.1111/jcpt.12287] [PMID: 26009929]

Majd, M.; Hashemian, F.; Hosseini, S.M.; Vahdat Shariatpanahi, M.; Sharifi, A. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: A pilot study. Iran. J. Pharm. Res., 2015, 14(3), 891-899.
[PMID: 26330878]

Alamdarsaravi, M.; Ghajar, A.; Noorbala, A.A.; Arbabi, M.; Emami, A.; Shahei, F.; Mirzania, M.; Jafarinia, M.; Afarideh, M.; Akhondzadeh, S. Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial. Psychiatry Res., 2017, 255, 59-65.
[http://dx.doi.org/10.1016/j.psychres.2017.05.029] [PMID: 28528242]

Baune, B.T.; Sampson, E.; Louise, J.; Hori, H.; Schubert, K.O.; Clark, S.R.; Mills, N.T.; Fourrier, C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur. Neuropsychopharmacol., 2021, 53, 34-46.
[http://dx.doi.org/10.1016/j.euroneuro.2021.07.092] [PMID: 34375789]

Berk, M.; Woods, R.L.; Nelson, M.R.; Shah, R.C.; Reid, C.M.; Storey, E.; Fitzgerald, S.; Lockery, J.E.; Wolfe, R.; Mohebbi, M.; Dodd, S.; Murray, A.M.; Stocks, N.; Fitzgerald, P.B.; Mazza, C.; Agustini, B.; McNeil, J.J. Effect of aspirin vs placebo on the prevention of depression in older people. JAMA Psychiatry, 2020, 77(10), 1012-1020.
[http://dx.doi.org/10.1001/jamapsychiatry.2020.1214] [PMID: 32492080]

Berk, M.; Mohebbi, M.; Dean, O.M.; Cotton, S.M.; Chanen, A.M.; Dodd, S.; Ratheesh, A.; Amminger, G.P.; Phelan, M.; Weller, A.; Mackinnon, A.; Giorlando, F.; Baird, S.; Incerti, L.; Brodie, R.E.; Ferguson, N.O.; Rice, S.; Schäfer, M.R.; Mullen, E.; Hetrick, S.; Kerr, M.; Harrigan, S.M.; Quinn, A.L.; Mazza, C.; McGorry, P.; Davey, C.G. Youth depression alleviation with anti-inflammatory agents (YoDA-A): A randomised clinical trial of rosuvastatin and aspirin. BMC Med., 2020, 18(1), 16.
[http://dx.doi.org/10.1186/s12916-019-1475-6] [PMID: 31948461]

Mahagna, H.; Amital, D.; Amital, H. A randomised, double‐blinded study comparing giving etoricoxib vs. placebo to female patients with fibromyalgia. Int. J. Clin. Pract., 2016, 70(2), 163-170.
[http://dx.doi.org/10.1111/ijcp.12760] [PMID: 26763773]

Fields, C.; Drye, L.; Vaidya, V.; Lyketsos, C.; Group, A.R. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am. J. Geriatr. Psychiatry, 2012, 20(6), 505-513.
[http://dx.doi.org/10.1097/JGP.0b013e318227f4da] [PMID: 21775876]

Iyengar, R.L.; Gandhi, S.; Aneja, A.; Thorpe, K.; Razzouk, L.; Greenberg, J.; Mosovich, S.; Farkouh, M.E. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am. J. Med., 2013, 126(11), e1011-e1018.
[http://dx.doi.org/10.1016/j.amjmed.2013.02.037]

Mohammadinejad, P.; Arya, P.; Esfandbod, M.; Kaviani, A.; Najafi, M.; Kashani, L.; Zeinoddini, A.; Emami, S.A.; Akhondzadeh, S. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients. Ann. Pharmacother., 2015, 49(9), 953-961.
[http://dx.doi.org/10.1177/1060028015592215] [PMID: 26139640]

Plane, J.M.; Shen, Y.; Pleasure, D.E.; Deng, W. Prospects for minocycline neuroprotection. Arch. Neurol., 2010, 67(12), 1442-1448.
[http://dx.doi.org/10.1001/archneurol.2010.191] [PMID: 20697034]

Bové, J.; Martínez-Vicente, M.; Vila, M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci., 2011, 12(8), 437-452.
[http://dx.doi.org/10.1038/nrn3068] [PMID: 21772323]

Stock, M.L.; Fiedler, K.J.; Acharya, S.; Lange, J.K.; Mlynarczyk, G.S.A.; Anderson, S.J.; McCormack, G.R.; Kanuri, S.H.; Kondru, N.C.; Brewer, M.T.; Carlson, S.A. Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities. Neuropharmacology, 2013, 73, 174-182.
[http://dx.doi.org/10.1016/j.neuropharm.2013.04.059] [PMID: 23748053]

Colovic, M.; Caccia, S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 791(1-2), 337-343.
[http://dx.doi.org/10.1016/S1570-0232(03)00247-2] [PMID: 12798193]

Emadi-Kouchak, H.; Mohammadinejad, P.; Asadollahi-Amin, A.; Rasoulinejad, M.; Zeinoddini, A.; Yalda, A.; Akhondzadeh, S. Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients. Int. Clin. Psychopharmacol., 2016, 31(1), 20-26.
[http://dx.doi.org/10.1097/YIC.0000000000000098] [PMID: 26465919]

Dean, O.M.; Kanchanatawan, B.; Ashton, M.; Mohebbi, M.; Ng, C.H.; Maes, M.; Berk, L.; Sughondhabirom, A.; Tangwongchai, S.; Singh, A.B.; McKenzie, H.; Smith, D.J.; Malhi, G.S.; Dowling, N.; Berk, M. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Aust. N. Z. J. Psychiatry, 2017, 51(8), 829-840.
[http://dx.doi.org/10.1177/0004867417709357] [PMID: 28578592]

Husain, M.I.; Chaudhry, I.B.; Husain, N.; Khoso, A.B.; Rahman, R.R.; Hamirani, M.M.; Hodsoll, J.; Qurashi, I.; Deakin, J.F.W.; Young, A.H. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial. J. Psychopharmacol., 2017, 31(9), 1166-1175.
[http://dx.doi.org/10.1177/0269881117724352] [PMID: 28857658]

Nettis, M.A.; Lombardo, G.; Hastings, C.; Zajkowska, Z.; Mariani, N.; Nikkheslat, N.; Worrell, C.; Enache, D.; McLaughlin, A.; Kose, M.; Sforzini, L.; Bogdanova, A.; Cleare, A.; Young, A.H.; Pariante, C.M.; Mondelli, V. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: Results from a double-blind randomised clinical trial. Neuropsychopharmacology, 2021, 46(5), 939-948.
[http://dx.doi.org/10.1038/s41386-020-00948-6] [PMID: 33504955]

Attwells, S.; Setiawan, E.; Rusjan, P.M.; Xu, C.; Kish, S.J.; Vasdev, N.; Houle, S.; Santhirakumar, A.; Meyer, J.H. A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. Transl. Psychiatry, 2021, 11(1), 334.
[http://dx.doi.org/10.1038/s41398-021-01450-3] [PMID: 34052828]

Vézina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot., 1975, 28(10), 721-726.
[http://dx.doi.org/10.7164/antibiotics.28.721] [PMID: 1102508]

Ignácio, Z.M.; Réus, G.Z.; Arent, C.O.; Abelaira, H.M.; Pitcher, M.R.; Quevedo, J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br. J. Clin. Pharmacol., 2016, 82(5), 1280-1290.
[http://dx.doi.org/10.1111/bcp.12845] [PMID: 26613210]

Murrough, J.W.; Abdallah, C.G.; Mathew, S.J. Targeting glutamate signalling in depression: Progress and prospects. Nat. Rev. Drug Discov., 2017, 16(7), 472-486.
[http://dx.doi.org/10.1038/nrd.2017.16] [PMID: 28303025]

Gould, T.D.; Zarate, C.A., Jr; Thompson, S.M. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Annu. Rev. Pharmacol. Toxicol., 2019, 59(1), 213-236.
[http://dx.doi.org/10.1146/annurev-pharmtox-010617-052811] [PMID: 30296896]

Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? Pharmacol. Ther., 2018, 190, 148-158.
[http://dx.doi.org/10.1016/j.pharmthera.2018.05.010] [PMID: 29803629]

Abdallah, C.G.; Averill, L.A.; Gueorguieva, R.; Goktas, S.; Purohit, P.; Ranganathan, M.; Sherif, M.; Ahn, K.H.; D’Souza, D.C.; Formica, R.; Southwick, S.M.; Duman, R.S.; Sanacora, G.; Krystal, J.H. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology, 2020, 45(6), 990-997.
[http://dx.doi.org/10.1038/s41386-020-0644-9] [PMID: 32092760]

Yaribeygi, H.; Ashrafizadeh, M.; Henney, N.C.; Sathyapalan, T.; Jamialahmadi, T.; Sahebkar, A. Neuromodulatory effects of anti-diabetes medications: A mechanistic review. Pharmacol. Res., 2020, 152, 104611.
[http://dx.doi.org/10.1016/j.phrs.2019.104611] [PMID: 31863868]

García-Bueno, B.; Pérez-Nievas, B.G.; Leza, J.C. Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases? Int. J. Neuropsychopharmacol., 2010, 13(10), 1411-1429.
[http://dx.doi.org/10.1017/S1461145710000970] [PMID: 20800014]

Sepanjnia, K.; Modabbernia, A.; Ashrafi, M.; Modabbernia, M.J.; Akhondzadeh, S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology, 2012, 37(9), 2093-2100.
[http://dx.doi.org/10.1038/npp.2012.58] [PMID: 22549115]

Lin, K.W.; Wroolie, T.E.; Robakis, T.; Rasgon, N.L. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Res., 2015, 230(3), 846-852.
[http://dx.doi.org/10.1016/j.psychres.2015.10.013] [PMID: 26602230]

Rasgon, N.; Lin, K.W.; Lin, J.; Epel, E.; Blackburn, E. Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: A preliminary study. Transl. Psychiatry, 2016, 6(1), e709.
[http://dx.doi.org/10.1038/tp.2015.187] [PMID: 26731446]

Miller, R.A.; Chu, Q.; Xie, J.; Foretz, M.; Viollet, B.; Birnbaum, M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature, 2013, 494(7436), 256-260.
[http://dx.doi.org/10.1038/nature11808] [PMID: 23292513]

Abdallah, M.S.; Mosalam, E.M.; Zidan, A.A.A.; Elattar, K.S.; Zaki, S.A.; Ramadan, A.N.; Ebeid, A.M. RETRACTED ARTICLE: The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Neurotherapeutics, 2020, 17(4), 1897-1906.
[http://dx.doi.org/10.1007/s13311-020-00878-7] [PMID: 32500486]

Walker, A.J.; Kim, Y.; Borissiouk, I.; Rehder, R.; Dodd, S.; Morris, G.; Nierenberg, A.A.; Maes, M.; Fernandes, B.S.; Dean, O.M.; Williams, L.J.; Eyre, H.A.; Kim, S.W.; Zoungas, S.; Carvalho, A.F.; Berk, M. Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neurosci. Biobehav. Rev., 2021, 128, 693-708.
[http://dx.doi.org/10.1016/j.neubiorev.2021.07.012] [PMID: 34265321]

Köhler-Forsberg, O.; Otte, C.; Gold, S.M.; Østergaard, S.D. Statins in the treatment of depression: Hype or hope? Pharmacol. Ther., 2020, 215, 107625.
[http://dx.doi.org/10.1016/j.pharmthera.2020.107625] [PMID: 32652185]

Zeiser, R. Immune modulatory effects of statins. Immunology, 2018, 154(1), 69-75.
[http://dx.doi.org/10.1111/imm.12902] [PMID: 29392731]

Santanello, N.C.; Barber, B.L.; Applegate, W.B.; Elam, J.; Curtis, C.; Hunninghake, D.B.; Gordon, D.J. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J. Am. Geriatr. Soc., 1997, 45(1), 8-14.
[http://dx.doi.org/10.1111/j.1532-5415.1997.tb00971.x] [PMID: 8994481]

Ghanizadeh, A.; Hedayati, A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress. Anxiety, 2013, 30(11), 1084-1088.
[http://dx.doi.org/10.1002/da.22195] [PMID: 24115188]

Stewart, R.A.; Sharples, K.J.; North, F.M.; Menkes, D.B.; Baker, J.; Simes, J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. Arch. Intern. Med., 2000, 160(20), 3144-3152.
[http://dx.doi.org/10.1001/archinte.160.20.3144] [PMID: 11074745]

Carlsson, C.M.; Papcke-Benson, K.; Carnes, M.; McBride, P.E.; Stein, J.H. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging, 2002, 19(10), 793-805.
[http://dx.doi.org/10.2165/00002512-200219100-00008] [PMID: 12390056]

Gougol, A.; Zareh-Mohammadi, N.; Raheb, S.; Farokhnia, M.; Salimi, S.; Iranpour, N.; Yekehtaz, H.; Akhondzadeh, S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. J. Psychopharmacol., 2015, 29(5), 575-581.
[http://dx.doi.org/10.1177/0269881115578160] [PMID: 25827645]

Chan, D.; Binks, S.; Nicholas, J.M.; Frost, C.; Cardoso, M.J.; Ourselin, S.; Wilkie, D.; Nicholas, R.; Chataway, J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: Secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol., 2017, 16(8), 591-600.
[http://dx.doi.org/10.1016/S1474-4422(17)30113-8] [PMID: 28600189]

Haghighi, M.; Khodakarami, S.; Jahangard, L.; Ahmadpanah, M.; Bajoghli, H.; Holsboer-Trachsler, E.; Brand, S. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. J. Psychiatr. Res., 2014, 58, 109-114.
[http://dx.doi.org/10.1016/j.jpsychires.2014.07.018] [PMID: 25130678]

Abbasi, S.H.; Mohammadinejad, P.; Shahmansouri, N.; Salehiomran, A.; Beglar, A.A.; Zeinoddini, A.; Forghani, S.; Akhondzadeh, S. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial. J. Affect. Disord., 2015, 183, 149-155.
[http://dx.doi.org/10.1016/j.jad.2015.04.049] [PMID: 26005776]

Arana, G.W.; Santos, A.B.; Laraia, M.T.; McLeod-Bryant, S.; Beale, M.D.; Rames, L.J.; Roberts, J.M.; Dias, J.K.; Molloy, M. Dexamethasone for the treatment of depression: A randomized, placebo- controlled, double-blind trial. Am. J. Psychiatry, 1995, 152(2), 265-267.
[http://dx.doi.org/10.1176/ajp.152.2.265] [PMID: 7840362]

DeBattista, C.; Posener, J.A.; Kalehzan, B.M.; Schatzberg, A.F. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study. Am. J. Psychiatry, 2000, 157(8), 1334-1337.
[http://dx.doi.org/10.1176/appi.ajp.157.8.1334] [PMID: 10910802]

Clayton, P.; Hill, M.; Bogoda, N.; Subah, S.; Venkatesh, R. Palmitoylethanolamide: A natural compound for health management. Int. J. Mol. Sci., 2021, 22(10), 5305.
[http://dx.doi.org/10.3390/ijms22105305] [PMID: 34069940]

Ghazizadeh-Hashemi, M.; Ghajar, A.; Shalbafan, M.R.; Ghazizadeh-Hashemi, F.; Afarideh, M.; Malekpour, F.; Ghaleiha, A.; Ardebili, M.E.; Akhondzadeh, S. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial. J. Affect. Disord., 2018, 232, 127-133.
[http://dx.doi.org/10.1016/j.jad.2018.02.057] [PMID: 29486338]

Liu, L.; Liu, C.; Wang, Y.; Wang, P.; Li, Y.; Li, B. Herbal medicine for anxiety, depression and insomnia. Curr. Neuropharmacol., 2015, 13(4), 481-493.
[http://dx.doi.org/10.2174/1570159X1304150831122734] [PMID: 26412068]

Yeung, W.F.; Chung, K.F.; Ng, K.Y.; Yu, Y.M.; Ziea, E.T.C.; Ng, B.F.L. A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression. J. Psychiatr. Res., 2014, 57, 165-175.
[http://dx.doi.org/10.1016/j.jpsychires.2014.05.016] [PMID: 24974002]

Matias, J.N.; Achete, G.; Campanari, G.S.S.; Guiguer, É.L.; Araújo, A.C.; Buglio, D.S.; Barbalho, S.M. A systematic review of the antidepressant effects of curcumin: Beyond monoamines theory. Aust. N. Z. J. Psychiatry, 2021, 55(5), 451-462.
[http://dx.doi.org/10.1177/0004867421998795] [PMID: 33673739]

Panahi, Y.; Badeli, R.; Karami, G.R.; Sahebkar, A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res., 2015, 29(1), 17-21.
[http://dx.doi.org/10.1002/ptr.5211] [PMID: 25091591]

Lopresti, A.L.; Maes, M.; Meddens, M.J.M.; Maker, G.L.; Arnoldussen, E.; Drummond, P.D. Curcumin and major depression: A randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change. Eur. Neuropsychopharmacol., 2015, 25(1), 38-50.
[http://dx.doi.org/10.1016/j.euroneuro.2014.11.015] [PMID: 25523883]

Lopresti, A.L.; Maes, M.; Maker, G.L.; Hood, S.D.; Drummond, P.D. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J. Affect. Disord., 2014, 167, 368-375.
[http://dx.doi.org/10.1016/j.jad.2014.06.001] [PMID: 25046624]

Sanmukhani, J.; Satodia, V.; Trivedi, J.; Patel, T.; Tiwari, D.; Panchal, B.; Goel, A.; Tripathi, C.B. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytother. Res., 2014, 28(4), 579-585.
[http://dx.doi.org/10.1002/ptr.5025] [PMID: 23832433]

Esmaily, H.; Sahebkar, A.; Iranshahi, M.; Ganjali, S.; Mohammadi, A.; Ferns, G.; Ghayour-Mobarhan, M. An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin. J. Integr. Med., 2015, 21(5), 332-338.
[http://dx.doi.org/10.1007/s11655-015-2160-z] [PMID: 25776839]

Yu, J.J.; Pei, L.B.; Zhang, Y.; Wen, Z.Y.; Yang, J.L. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder. J. Clin. Psychopharmacol., 2015, 35(4), 406-410.
[http://dx.doi.org/10.1097/JCP.0000000000000352] [PMID: 26066335]

Lopresti, A.L.; Drummond, P.D. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study. J. Affect. Disord., 2017, 207, 188-196.
[http://dx.doi.org/10.1016/j.jad.2016.09.047] [PMID: 27723543]

Kanchanatawan, B.; Tangwongchai, S.; Sughondhabhirom, A.; Suppapitiporn, S.; Hemrunrojn, S.; Carvalho, A.F.; Maes, M. Add-on treatment with curcumin has antidepressive effects in thai patients with major depression: Results of a randomized double-blind placebo-controlled study. Neurotox. Res., 2018, 33(3), 621-633.
[http://dx.doi.org/10.1007/s12640-017-9860-4] [PMID: 29327213]

Bergman, J.; Miodownik, C.; Bersudsky, Y.; Sokolik, S.; Lerner, P.P.; Kreinin, A.; Polakiewicz, J.; Lerner, V. Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol., 2013, 36(3), 73-77.
[http://dx.doi.org/10.1097/WNF.0b013e31828ef969] [PMID: 23673908]

Cao, Z.Y.; Liu, Y.Z.; Li, J.M.; Ruan, Y.M.; Yan, W.J.; Zhong, S.Y.; Zhang, T.; Liu, L.L.; Wu, R.; Wang, B.; Wang, W.; Bi, X.Y.; Wang, Y.X.; Su, W.J.; Jiang, C.L. Glycyrrhizic acid as an adjunctive treatment for depression through anti-inflammation: A randomized placebo-controlled clinical trial. J. Affect. Disord., 2020, 265, 247-254.
[http://dx.doi.org/10.1016/j.jad.2020.01.048] [PMID: 32090748]

Molendijk, M.; Molero, P.; Sánchez-Pedreño, O.F.; Van der Does, W.; Martínez-González, A.M. Diet quality and depression risk: A systematic review and dose-response meta-analysis of prospective studies. J. Affect. Disord., 2018, 226, 346-354.
[http://dx.doi.org/10.1016/j.jad.2017.09.022] [PMID: 29031185]

Yang, Y.; Kim, Y.; Je, Y. Fish consumption and risk of depression: Epidemiological evidence from prospective studies. Asia-Pac. Psychiatry, 2018, 10(4), e12335.
[http://dx.doi.org/10.1111/appy.12335] [PMID: 30238628]

Su, K.P.; Lai, H.C.; Yang, H.T.; Su, W.P.; Peng, C.Y.; Chang, J.P.C.; Chang, H.C.; Pariante, C.M. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol. Psychiatry, 2014, 76(7), 559-566.
[http://dx.doi.org/10.1016/j.biopsych.2014.01.008] [PMID: 24602409]

Martins, J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J. Am. Coll. Nutr., 2009, 28(5), 525-542.
[http://dx.doi.org/10.1080/07315724.2009.10719785] [PMID: 20439549]

Ortega, M.A.; Fraile-Martínez, Ó.; García-Montero, C.; Alvarez-Mon, M.A.; Lahera, G.; Monserrat, J.; Llavero-Valero, M.; Gutiérrez-Rojas, L.; Molina, R.; Rodríguez-Jimenez, R.; Quintero, J.; De Mon, M.A. Biological role of nutrients, food and dietary patterns in the prevention and clinical management of major depressive disorder. Nutrients, 2022, 14(15), 3099.
[http://dx.doi.org/10.3390/nu14153099] [PMID: 35956276]

Mee-inta, O.; Zhao, Z.W.; Kuo, Y.M. Physical exercise inhibits inflammation and microglial activation. Cells, 2019, 8(7), 691.
[http://dx.doi.org/10.3390/cells8070691] [PMID: 31324021]

Ding, Y.; Xu, X. Anti-inflammatory effect of exercise training through reducing inflammasome activation-related inflammatory cytokine levels in overweight/obese populations: A systematic review and meta-analysis. Complement. Ther. Clin. Pract., 2022, 49, 101656.
[http://dx.doi.org/10.1016/j.ctcp.2022.101656] [PMID: 36055106]

Lee, J.; Gierc, M.; Vila-Rodriguez, F.; Puterman, E.; Faulkner, G. Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone: A systematic review and meta-analysis of randomized controlled trials. J. Affect. Disord., 2021, 295, 1494-1511.
[http://dx.doi.org/10.1016/j.jad.2021.09.043] [PMID: 34565591]

Bigarella, L.G.; Ballotin, V.R.; Mazurkiewicz, L.F.; Ballardin, A.C.; Rech, D.L.; Bigarella, R.L.; Selistre, L.S. Exercise for depression and depressive symptoms in older adults: An umbrella review of systematic reviews and Meta-analyses. Aging Ment. Health, 2022, 26(8), 1503-1513.
[http://dx.doi.org/10.1080/13607863.2021.1951660] [PMID: 34328049]

Xie, Y.; Wu, Z.; Sun, L.; Zhou, L.; Wang, G.; Xiao, L.; Wang, H. The effects and mechanisms of exercise on the treatment of depression. Front. Psychiatry, 2021, 12, 705559.
[http://dx.doi.org/10.3389/fpsyt.2021.705559] [PMID: 34803752]

Marinovic, D.A.; Hunter, R.L. Examining the interrelationships between mindfulness‐based interventions, depression, inflammation, and cancer survival. CA Cancer J. Clin., 2022, 72(5), 490-502.
[http://dx.doi.org/10.3322/caac.21733] [PMID: 35709081]

Sanada, K.; Montero-Marin, J.; Barceló-Soler, A.; Ikuse, D.; Ota, M.; Hirata, A.; Yoshizawa, A.; Hatanaka, R.; Valero, M.S.; Demarzo, M.; Campayo, J.G.; Iwanami, A. Effects of mindfulness-based interventions on biomarkers and low-grade inflammation in patients with psychiatric disorders: A meta-analytic review. Int. J. Mol. Sci., 2020, 21(7), 2484.
[http://dx.doi.org/10.3390/ijms21072484] [PMID: 32260096]

Reangsing, C.; Punsuwun, S.; Schneider, J.K. Effects of mindfulness interventions on depressive symptoms in adolescents: A meta-analysis. Int. J. Nurs. Stud., 2021, 115, 103848.
[http://dx.doi.org/10.1016/j.ijnurstu.2020.103848] [PMID: 33383273]

Haller, H.; Anheyer, D.; Cramer, H.; Dobos, G. Complementary therapies for clinical depression: An overview of systematic reviews. BMJ Open, 2019, 9(8), e028527.
[http://dx.doi.org/10.1136/bmjopen-2018-028527] [PMID: 31383703]

Johannsen, M.; Nissen, E.R.; Lundorff, M.; O’Toole, M.S. Mediators of acceptance and mindfulness-based therapies for anxiety and depression: A systematic review and meta-analysis. Clin. Psychol. Rev., 2022, 94, 102156.
[http://dx.doi.org/10.1016/j.cpr.2022.102156] [PMID: 35483275]

Köhler, O.; Benros, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 2014, 71(12), 1381-1391.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.1611] [PMID: 25322082]

Adzic, M.; Brkic, Z.; Mitic, M.; Francija, E.; Jovicic, M.J.; Radulovic, J.; Maric, N.P. Therapeutic strategies for treatment of inflammation-related depression. Curr. Neuropharmacol., 2018, 16(2), 176-209.
[PMID: 28847294]

Kopschina Feltes, P.; Doorduin, J.; Klein, H.C.; Juárez-Orozco, L.E.; Dierckx, R.A.J.O.; Moriguchi-Jeckel, C.M.; de Vries, E.F.J. Anti-inflammatory treatment for major depressive disorder: Implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J. Psychopharmacol., 2017, 31(9), 1149-1165.
[http://dx.doi.org/10.1177/0269881117711708] [PMID: 28653857]

Shariq, A.S.; Brietzke, E.; Rosenblat, J.D.; Barendra, V.; Pan, Z.; McIntyre, R.S. Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 83, 86-91.
[http://dx.doi.org/10.1016/j.pnpbp.2018.01.003] [PMID: 29309829]

Malhi, G.S.; Outhred, T.; Hamilton, A.; Boyce, P.M.; Bryant, R.; Fitzgerald, P.B.; Lyndon, B.; Mulder, R.; Murray, G.; Porter, R.J.; Singh, A.B.; Fritz, K. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. Med. J. Aust., 2018, 208(4), 175-180.
[http://dx.doi.org/10.5694/mja17.00659] [PMID: 29490210]

Undurraga, J.; Baldessarini, R.J. Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology, 2012, 37(4), 851-864.
[http://dx.doi.org/10.1038/npp.2011.306] [PMID: 22169941]

Matveychuk, D.; Thomas, R.K.; Swainson, J.; Khullar, A.; MacKay, M.A.; Baker, G.B.; Dursun, S.M. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther. Adv. Psychopharmacol., 2020, 10.
[http://dx.doi.org/10.1177/2045125320916657] [PMID: 32440333]

Nikkheslat, N. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. Brain Behav. Immun.-. Health, 2021, 18, 100383.
[http://dx.doi.org/10.1016/j.bbih.2021.100383] [PMID: 34849492]

Li, J.M.; Liu, L.L.; Su, W.J.; Wang, B.; Zhang, T.; Zhang, Y.; Jiang, C.L. Ketamine may exert antidepressant effects via suppressing NLRP3 inflammasome to upregulate AMPA receptors. Neuropharmacology, 2019, 146, 149-153.
[http://dx.doi.org/10.1016/j.neuropharm.2018.11.022] [PMID: 30496753]

Carvalho, A.F.; Sharma, M.S.; Brunoni, A.R.; Vieta, E.; Fava, G.A. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychother. Psychosom., 2016, 85(5), 270-288.
[http://dx.doi.org/10.1159/000447034] [PMID: 27508501]

Ahrnsbrak, R.; Stagnitti, M.N. Average expenditures per prescription antidepressant fill in the U.S. civilian noninstitutionalized population by select sociodemographic characteristics. In: Statistical Brief (Medical Expenditure Panel Survey (US); Rockville (MD), 2001.

Shah, D.; Allen, L.; Zheng, W.; Madhavan, S.S.; Wei, W.; LeMasters, T.J.; Sambamoorthi, U. Economic burden of treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder in the US. PharmacoEconomics, 2021, 39(6), 639-651.
[http://dx.doi.org/10.1007/s40273-021-01029-2] [PMID: 33904144]

Kuehner, C. Why is depression more common among women than among men? Lancet Psychiatry, 2017, 4(2), 146-158.
[http://dx.doi.org/10.1016/S2215-0366(16)30263-2] [PMID: 27856392]

Maslej, M.M.; Furukawa, T.A.; Cipriani, A.; Andrews, P.W.; Sanches, M.; Tomlinson, A.; Volkmann, C.; McCutcheon, R.A.; Howes, O.; Guo, X.; Mulsant, B.H. Individual differences in response to antidepressants. JAMA Psychiatry, 2021, 78(5), 490-497.
[http://dx.doi.org/10.1001/jamapsychiatry.2020.4564] [PMID: 33595620]

Su, M.; Ouyang, X.; Song, Y. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio in depression: A meta-analysis. J. Affect. Disord., 2022, 308, 375-383.
[http://dx.doi.org/10.1016/j.jad.2022.04.038] [PMID: 35439466]

Cheng, Y.; Wang, Y.; Wang, X.; Jiang, Z.; Zhu, L.; Fang, S. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in depression: An updated systematic review and meta-analysis. Front. Psychiatry, 2022, 13, 893097.
[http://dx.doi.org/10.3389/fpsyt.2022.893097] [PMID: 35782448]

Meng, F.; Yan, X.; Qi, J.; He, F. Association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio with depression: A cross-sectional analysis of the NHANES data. J. Affect. Disord., 2022, 315, 168-173.
[http://dx.doi.org/10.1016/j.jad.2022.08.004] [PMID: 35932936]

Schatzberg, A.F. Scientific issues relevant to improving the diagnosis, risk assessment, and treatment of major depression. Am. J. Psychiatry, 2019, 176(5), 342-347.
[http://dx.doi.org/10.1176/appi.ajp.2019.19030273] [PMID: 31039643]

Li, J.M.; Jiang, C.L. Biological diagnosis of depression: A biomarker panel from several nonspecial indicators instead of the specific biomarker(s). Neuropsychiatr. Dis. Treat., 2022, 18, 3067-3071.
[http://dx.doi.org/10.2147/NDT.S393553] [PMID: 36606185]

Franco, R.; Fernández-Suárez, D. Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol., 2015, 131, 65-86.
[http://dx.doi.org/10.1016/j.pneurobio.2015.05.003] [PMID: 26067058]

Almolda, B.; de Labra, C.; Barrera, I.; Gruart, A.; Delgado-Garcia, J.M.; Villacampa, N.; Vilella, A.; Hofer, M.J.; Hidalgo, J.; Campbell, I.L.; González, B.; Castellano, B. Alterations in microglial phenotype and hippocampal neuronal function in transgenic mice with astrocyte-targeted production of interleukin-10. Brain Behav. Immun., 2015, 45, 80-97.
[http://dx.doi.org/10.1016/j.bbi.2014.10.015] [PMID: 25449577]

Li, Z.; Ma, L.; Kulesskaya, N.; Võikar, V.; Tian, L. Microglia are polarized to M1 type in high-anxiety inbred mice in response to lipopolysaccharide challenge. Brain Behav. Immun., 2014, 38, 237-248.
[http://dx.doi.org/10.1016/j.bbi.2014.02.008] [PMID: 24561490]

Zhang, L.; Zhang, J.; You, Z. Switching of the microglial activation phenotype is a possible treatment for depression disorder. Front. Cell. Neurosci., 2018, 12, 306.
[http://dx.doi.org/10.3389/fncel.2018.00306] [PMID: 30459555]

Chhor, V.; Le Charpentier, T.; Lebon, S.; Oré, M.V.; Celador, I.L.; Josserand, J.; Degos, V.; Jacotot, E.; Hagberg, H.; Sävman, K.; Mallard, C.; Gressens, P.; Fleiss, B. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun., 2013, 32, 70-85.
[http://dx.doi.org/10.1016/j.bbi.2013.02.005] [PMID: 23454862]

Miki, A.; Honda, S.; Inoue, Y.; Yamada, Y.; Nakamura, M. Foveal depression and related factors in patients with a history of retinopathy of prematurity. Ophthalmologica, 2018, 240(2), 106-110.
[http://dx.doi.org/10.1159/000488368] [PMID: 29742514]

Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflammation, 2014, 11(1), 98.
[http://dx.doi.org/10.1186/1742-2094-11-98] [PMID: 24889886]

Kobayashi, K.; Imagama, S.; Ohgomori, T.; Hirano, K.; Uchimura, K.; Sakamoto, K.; Hirakawa, A.; Takeuchi, H.; Suzumura, A.; Ishiguro, N.; Kadomatsu, K. Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis., 2013, 4(3), e525.
[http://dx.doi.org/10.1038/cddis.2013.54] [PMID: 23470532]

Cheng, Y.; Pardo, M.; Armini, R.S.; Martinez, A.; Mouhsine, H.; Zagury, J.F.; Jope, R.S.; Beurel, E. Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior. Brain Behav. Immun., 2016, 53, 207-222.
[http://dx.doi.org/10.1016/j.bbi.2015.12.012] [PMID: 26772151]

Martin, M.; Rehani, K.; Jope, R.S.; Michalek, S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol., 2005, 6(8), 777-784.
[http://dx.doi.org/10.1038/ni1221] [PMID: 16007092]

Wu, T.Y.; Liu, L.; Zhang, W.; Zhang, Y.; Liu, Y.Z.; Shen, X.L.; Gong, H.; Yang, Y.Y.; Bi, X.Y.; Jiang, C.L.; Wang, Y.X. High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior. J. Psychiatr. Res., 2015, 64, 99-106.
[http://dx.doi.org/10.1016/j.jpsychires.2015.02.016] [PMID: 25795092]

Gong, H.; Su, W.J.; Cao, Z.Y.; Lian, Y.J.; Peng, W.; Liu, Y.Z.; Zhang, Y.; Liu, L.L.; Wu, R.; Wang, B.; Zhang, T.; Wang, Y.X.; Jiang, C.L. Hippocampal Mrp8/14 signaling plays a critical role in the manifestation of depressive-like behaviors in mice. J. Neuroinflammation, 2018, 15(1), 252.
[http://dx.doi.org/10.1186/s12974-018-1296-0] [PMID: 30180864]

Cao, X.; Li, L.P.; Wang, Q.; Wu, Q.; Hu, H.H.; Zhang, M.; Fang, Y.Y.; Zhang, J.; Li, S.J.; Xiong, W.C.; Yan, H.C.; Gao, Y.B.; Liu, J.H.; Li, X.W.; Sun, L.R.; Zeng, Y.N.; Zhu, X.H.; Gao, T.M. Astrocyte-derived ATP modulates depressive-like behaviors. Nat. Med., 2013, 19(6), 773-777.
[http://dx.doi.org/10.1038/nm.3162] [PMID: 23644515]

Rana, T.; Behl, T.; Mehta, V.; Uddin, M.S.; Bungau, S. Molecular insights into the therapeutic promise of targeting HMGB1 in depression. Pharmacol. Rep., 2021, 73(1), 31-42.
[http://dx.doi.org/10.1007/s43440-020-00163-6] [PMID: 33015736]

Wang, B.; Huang, X.; Pan, X.; Zhang, T.; Hou, C.; Su, W.J.; Liu, L.L.; Li, J.M.; Wang, Y.X. Minocycline prevents the depressive-like behavior through inhibiting the release of HMGB1 from microglia and neurons. Brain Behav. Immun., 2020, 88, 132-143.
[http://dx.doi.org/10.1016/j.bbi.2020.06.019] [PMID: 32553784]

Wang, B.; Lian, Y.J.; Su, W.J.; Peng, W.; Dong, X.; Liu, L.L.; Gong, H.; Zhang, T.; Jiang, C.L.; Wang, Y.X. HMGB1 mediates depressive behavior induced by chronic stress through activating the kynurenine pathway. Brain Behav. Immun., 2018, 72, 51-60.
[http://dx.doi.org/10.1016/j.bbi.2017.11.017] [PMID: 29195782]

Wang, B.; Lian, Y.J.; Dong, X.; Peng, W.; Liu, L.L.; Su, W.J.; Gong, H.; Zhang, T.; Jiang, C.L.; Li, J.S.; Wang, Y.X. Glycyrrhizic acid ameliorates the kynurenine pathway in association with its antidepressant effect. Behav. Brain Res., 2018, 353, 250-257.
[http://dx.doi.org/10.1016/j.bbr.2018.01.024] [PMID: 29366745]

Lian, Y.J.; Gong, H.; Wu, T.Y.; Su, W.J.; Zhang, Y.; Yang, Y.Y.; Peng, W.; Zhang, T.; Zhou, J.R.; Jiang, C.L.; Wang, Y.X. Ds-HMGB1 and fr-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. Brain Behav. Immun., 2017, 59, 322-332.
[http://dx.doi.org/10.1016/j.bbi.2016.09.017] [PMID: 27647532]

Paik, S.; Kim, J.K.; Silwal, P.; Sasakawa, C.; Jo, E.K. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell. Mol. Immunol., 2021, 18(5), 1141-1160.
[http://dx.doi.org/10.1038/s41423-021-00670-3] [PMID: 33850310]

Kaufmann, F.N.; Costa, A.P.; Ghisleni, G.; Diaz, A.P.; Rodrigues, A.L.S.; Peluffo, H.; Kaster, M.P. NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain Behav. Immun., 2017, 64, 367-383.
[http://dx.doi.org/10.1016/j.bbi.2017.03.002] [PMID: 28263786]

Zhang, Y.; Liu, L.; Peng, Y.L.; Liu, Y.Z.; Wu, T.Y.; Shen, X.L.; Zhou, J.R.; Sun, D.Y.; Huang, A.J.; Wang, X.; Wang, Y.X.; Jiang, C.L. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci. Ther., 2014, 20(2), 119-124.
[http://dx.doi.org/10.1111/cns.12170] [PMID: 24279434]

Su, W.J.; Zhang, Y.; Chen, Y.; Gong, H.; Lian, Y.J.; Peng, W.; Liu, Y.Z.; Wang, Y.X.; You, Z.L.; Feng, S.J.; Zong, Y.; Lu, G.C.; Jiang, C.L. NLRP3 gene knockout blocks NF-kappaB and MAPK signaling pathway in CUMS-induced depression mouse model. Behav Brain Res, 2017, 322(Pt A), 1-8.

Zhang, Y.; Liu, L.; Liu, Y.Z.; Shen, X.L.; Wu, T.Y.; Zhang, T.; Wang, W.; Wang, Y.X.; Jiang, C.L. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int. J. Neuropsychopharmacol., 2015, 18(8), pyv006-pyv006.
[http://dx.doi.org/10.1093/ijnp/pyv006] [PMID: 25603858]

Su, W.J.; Peng, W.; Gong, H.; Liu, Y.Z.; Zhang, Y.; Lian, Y.J.; Cao, Z.Y.; Wu, R.; Liu, L.L.; Wang, B.; Wang, Y.X.; Jiang, C.L. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J. Neuroinflammation, 2017, 14(1), 210.
[http://dx.doi.org/10.1186/s12974-017-0985-4] [PMID: 29084550]

Xia, C.Y.; Guo, Y.X.; Lian, W.W.; Yan, Y.; Ma, B.Z.; Cheng, Y.C.; Xu, J.K.; He, J.; Zhang, W.K. The NLRP3 inflammasome in depression: Potential mechanisms and therapies. Pharmacol. Res., 2023, 187, 106625.
[http://dx.doi.org/10.1016/j.phrs.2022.106625] [PMID: 36563870]

Li, W.; Niu, L.; Liu, Z.; Xu, X.; Shi, M.; Zhang, Y.; Deng, Y.; He, J.; Xu, Y.; Wan, W.; Sun, Q.; Zhong, X.; Cao, W. Inhibition of the NLRP3 inflammasome with MCC950 prevents chronic social isolation-induced depression-like behavior in male mice. Neurosci. Lett., 2021, 765, 136290.
[http://dx.doi.org/10.1016/j.neulet.2021.136290] [PMID: 34644625]

Wang, D.; Wang, H.; Gao, H.; Zhang, H.; Zhang, H.; Wang, Q.; Sun, Z. P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes. Cell Biosci., 2020, 10(1), 28.
[http://dx.doi.org/10.1186/s13578-020-00388-1] [PMID: 32166013]

Yue, N.; Huang, H.; Zhu, X.; Han, Q.; Wang, Y.; Li, B.; Liu, Q.; Wu, G.; Zhang, Y.; Yu, J. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors. J. Neuroinflammation, 2017, 14(1), 102.
[http://dx.doi.org/10.1186/s12974-017-0865-y] [PMID: 28486969]

Bhattacharya, A.; Lord, B.; Grigoleit, J.S.; He, Y.; Fraser, I.; Campbell, S.N.; Taylor, N.; Aluisio, L.; O’Connor, J.C.; Papp, M.; Chrovian, C.; Carruthers, N.; Lovenberg, T.W.; Letavic, M.A. Neuropsychopharmacology of JNJ-55308942: Evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology, 2018, 43(13), 2586-2596.
[http://dx.doi.org/10.1038/s41386-018-0141-6] [PMID: 30026598]

Farooq, R.K.; Tanti, A.; Ainouche, S.; Roger, S.; Belzung, C.; Camus, V.A. P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. Psychoneuroendocrinology, 2018, 97, 120-130.
[http://dx.doi.org/10.1016/j.psyneuen.2018.07.016] [PMID: 30015007]

Liu, L.L.; Li, J.M.; Su, W.J.; Wang, B.; Jiang, C.L. Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. Brain Behav. Immun., 2019, 81, 188-197.
[http://dx.doi.org/10.1016/j.bbi.2019.06.012] [PMID: 31181346]

Drevets, W.C.; Wittenberg, G.M.; Bullmore, E.T.; Manji, H.K. Immune targets for therapeutic development in depression: towards precision medicine. Nat. Rev. Drug Discov., 2022, 21(3), 224-244.
[http://dx.doi.org/10.1038/s41573-021-00368-1] [PMID: 35039676]

Cattaneo, A.; Ferrari, C.; Turner, L.; Mariani, N.; Enache, D.; Hastings, C.; Kose, M.; Lombardo, G.; McLaughlin, A.P.; Nettis, M.A.; Nikkheslat, N.; Sforzini, L.; Worrell, C.; Zajkowska, Z.; Cattane, N.; Lopizzo, N.; Mazzelli, M.; Pointon, L.; Cowen, P.J.; Cavanagh, J.; Harrison, N.A.; de Boer, P.; Jones, D.; Drevets, W.C.; Mondelli, V.; Bullmore, E.T.; Pariante, C.M. Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study. Transl. Psychiatry, 2020, 10(1), 232.
[http://dx.doi.org/10.1038/s41398-020-00874-7] [PMID: 32699209]

Leday, G.G.R.; Vértes, P.E.; Richardson, S.; Greene, J.R.; Regan, T.; Khan, S.; Henderson, R.; Freeman, T.C.; Pariante, C.M.; Harrison, N.A.; Perry, V.H.; Drevets, W.C.; Wittenberg, G.M.; Bullmore, E.T.; Bullmore, E.; Vertes, P.; Cardinal, R.; Richardson, S.; Leday, G.; Freeman, T.; Regan, T.; Hume, D.; Wu, Z.; Pariante, C.; Cattaneo, A.; Zunszain, P.; Borsini, A.; Stewart, R.; Chandran, D.; Carvalho, L.; Bell, J.; Souza-Teodoro, L.; Perry, H.; Harrison, N.; Drevets, W.; Wittenberg, G.; Jones, D.; Bullmore, E.; Khan, S.; Stylianou, A.; Henderson, R. Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder. Biol. Psychiatry, 2018, 83(1), 70-80.
[http://dx.doi.org/10.1016/j.biopsych.2017.01.021] [PMID: 28688579]

van Eeden, W.A.; van Hemert, A.M.; Carlier, I.V.E.; Penninx, B.W.J.H.; Lamers, F.; Fried, E.I.; Schoevers, R.; Giltay, E.J. Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. Transl. Psychiatry, 2020, 10(1), 235.
[http://dx.doi.org/10.1038/s41398-020-00920-4] [PMID: 32669537]

Spijker, S.; Van Zanten, J.S.; De Jong, S.; Penninx, B.W.J.H.; van Dyck, R.; Zitman, F.G.; Smit, J.H.; Ylstra, B.; Smit, A.B.; Hoogendijk, W.J.G. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol. Psychiatry, 2010, 68(2), 179-186.
[http://dx.doi.org/10.1016/j.biopsych.2010.03.017] [PMID: 20471630]

Lucido, M.J.; Bekhbat, M.; Goldsmith, D.R.; Treadway, M.T.; Haroon, E.; Felger, J.C.; Miller, A.H. Aiding and abetting anhedonia: Impact of inflammation on the brain and pharmacological implications. Pharmacol. Rev., 2021, 73(3), 1084-1117.
[http://dx.doi.org/10.1124/pharmrev.120.000043] [PMID: 34285088]